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ABSTRACT 
Pluripotent stem cells hold great promise in regenerative medicine and drug 
development due to their developmental potential towards multiple lineages. However, 
there are still hurdles to overcome before these cells are safe enough for clinical use 
even though attempts have already been initiated. 
To generate pluripotent cell populations for specific clinical purposes, it is crucial to 
understand the regulatory role of microenvironmental cues as well as factors and 
signaling pathways that control their cellular phenotype. The main purpose of this work 
has been to study how pluripotent cells may change due to handling and how 
microenvironmental cues may influence the characteristics of pluripotent cells. 
An effective and robust cryopreservation system is necessary in order to store 
pluripotent stem cells. We compared a standard freezing method with a novel 
chemically defined xeno-free solution and found that the number of frozen colonies vs. 
the number of surviving colonies improved significantly with the new method. Using a 
live/dead assay we obtained 90-96% viability without any impact on proliferation using 
the new method, compared with the standard freezing procedure (49%). Furthermore, 
to enable up-scaling of undifferentiated cells, it is important to passage cells with 
limited effect on cell quality. We investigated whether different passaging techniques 
can affect the properties of stem cells. We found that cells passaged in the presence of 
ROCKi displayed alterations in actin organization. We also found decreased expression 
of genes encoding common pluripotency markers in cells enzymatically passaged 
compared to mechanical passaged cells, irrespective of the use of ROCKi, but no 
correlation to histone modification on the promoters of these genes. We found that the 
effect of enzymatic passaging and ROCKi were at least in part reversible. 
It is relevant to investigate differences between early and late passages when it comes 
to chromatin state and expression of stem cell markers. We analyzed the gene 
expression and histone acetylation levels in the promoters of well-defined transcription 
factors associated with pluripotent state. The acetylation analysis was focused on 
lysines 8 and 12 on histone H4, since acetylation of these residues has been associated 
with the interaction of the SWI/SNF complex as well as DNA damage. We could detect 
variations in histone acetylation levels and gene expression between different cell lines. 
However we found no significant correlation between either histone acetylation and 
gene expression levels, nor with these parameters alone and passage number. This 
suggests that other parameters should be evaluated for screening of clinically suitable 
pluripotent stem cells. 
Finally, prolonged culturing of stem cells in vitro may select for cells with genetic 
changes which often result in growth advantages by acquired mutations, called culture 
adaptation. By performing a comparative in vivo and in vitro study on human 
embryonic stem cell lines we were able to identify chromosomal aberrations that had 
occurred in vivo. We also found an amplification of the whole X chromosome in cells 
differentiated in vivo. The potential of precancerous mutations in in vivo conditions is 
important to consider for safety measures, and underlines the necessity to remove all 
pluripotent stem cells from differentiated populations that will be transplanted.  
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1 INTRODUCTION 
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tem cell biology became a key player in developmental research, starting with 
the research of human infertility and in vitro fertilization. The wish of the 2010 
Nobel Laureate in Physiology or Medicine Robert G Edwards to grow cell lines 
from fertilized mouse eggs and through these cells produce blood or nerves in vitro was 
a starting point for this field of research.  
Stem cell therapy is now being discussed for possible treatments for many diseases 
where neurodegenerative diseases such as Alzheimer’s disease, Parkinson´s disease, 
and metabolic diseases such as diabetes along with many others are being widely 
studied. 
Human embryonic stem cell lines derived from the inner cell mass of fertilized 
embryos, and later also human induced pluripotent stem cell lines originating from 
somatic cells reprogrammed by using four transcription factors, have both the ability to 
form all cell types within the human body through the process of differentiation.  
This introduction will bring to light the possibilities of these cells and how the different 
influences that they are subject to may impact their quality, and therefore also impact 
their future use in the treatment of severe diseases. 
 
  
S
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1.1 EMBRYOGENESIS 
Human development begins when a sperm fertilizes an egg and creates a single cell that 
has the potential to form an entire organism, a process known as embryogenesis. 
Embryogenesis is an event that occurs both in plant and animal development and is the 
process where the embryo forms and develops until it becomes a fetus. In humans, the 
fertilization takes place in the ampulla of the oviduct when the spermatozoan penetrates 
through the zona pellucida of the oocyte, resulting in the formation of the zygote 
(Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. Human embryo development. Embryogenesis starts with the union of a male sperm and 
a female oocyte, resulting in fusion of their genetic material (1). The zygote undergoes cleavage to 
increase the number of cells (2). After the 8-cell stage the embryo undergoes compaction where the 
cells bind tightly together (3). After compaction, the embryo is in the morula stage and cavitation 
occur where the outermost cell layer- trophoblast secrets fluid into the morula (4). When the number 
of cells reaches 40-150 the central fluid-filled cavity is formed, called blastocoelic cavity (5). Now 
the zona pellucida starts to degenerate, allowing the embryo to grow, hatching (6). This stage is 
reached after approximately 6 days after fertilization and is referred to as pre-implantation stage, and 
each cell until now is totipotent. Now implantation to the uterine epithelium occurs (8).  At day 9 the 
cell mass starts to differentiate, trophoblast cells will eventually form the placenta, hypoblast 
(primitive endoderm) will form the extra embryonic tissues such as the yolk sac, and the epiblast 
also referred to as the primary ectoderm forms all three germ layers of the trilaminar germ disc in a 
process called gastrulation (8-9).  Illustrated by Emma Nyrell, Modified from www.wikipedia.org.
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1.2 STEM CELLS 
A number of functional changes which are important to enhance the mammalian 
embryo development take place during the short period of implantation in the 
endometrial wall. Truly naїve embryonic stem cells (ESCs) are found in the transition 
from morula to blastocyst, and epigenetic reprogramming, such as the re-activation of 
the paternal X chromosome is essential for its further development1.  
Stem cells (SCs) are non-specialized cells and are found in all multi-cellular organisms, 
having two distinctive characteristics; they can undergo unlimited cell divisions 
(mitosis), and they can become more specialized cell types through differentiation. 
Those specific characteristics make these cells a powerful model system for studies of 
cellular identity and early mammalian development.  
 
1.2.1 Definition and classification 
For a cell to be defined as a SC, there are three major criteria that have to be fulfilled: 
(1) SCs are unspecialized for any particular function, (2) upon signaling and the right 
conditions SCs can differentiate into more specialized cell types within the body of a 
multi-cellular organism, (3) where they can self-renew indefinitely to produce more 
SCs2.  
There are four defined types of SCs: two physiological which are present at different 
stages of life-  ESCs and adult stem cells, one engineered or “induced” known as 
induced pluripotent stem cells (iPSCs), and pathological cells present in cancers having 
some stem cell properties known as cancer stem cells (CSCs).  
ESCs are found in the developing embryo and have the ability to differentiate into all 
cell types found in the body, but they also maintain the normal turnover of regenerative 
organs, such as blood and skin. The adult SCs are found throughout the body after 
development. Unlike ESCs, they can only differentiate to cell types from the organ that 
they originate, making them multipotent, e.g. a blood SCs can only differentiate to 
various types blood cells. 
 
There are three stages of differentiation potential among SCs: 
 
Totipotent cells have total potential. They can differentiate into all three germ layers, 
but also into extra-embryonic tissue (trophectoderm), such as the cells developing into 
the placenta. The zygote and the first stages of the embryo are the only cells that can be 
characterized as totipotent3 and it occurs the moment the sperm fertilizes an egg and 
create a single cell. In the initial hours and days following fertilization, this single 
totipotent cell divides into more totipotent cells that are exact copies of the original. 
Evidence of the totipotent nature of these first dividing cells is exemplified by the 
development of identical twins any time during the first four divisions. 
Approximately four days after fertilization, the totipotent cells start to specialize and 
form a cluster of cells known as a blastocyst (Figure 1; illustration 4-5). The blastocyst 
has yet another group of cells known as the inner cell mass (ICM) and it is these 
pluripotent cells that will go on to create most of the cells and tissues in the human 
body. 
 
Pluripotent cells can be isolated, adapted and propagated indefinitely under the right 
conditions in an undifferentiated state in vitro.  They are derived from the ICM of a pre-
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implantation blastocyst stage embryo or morula stage embryo (Figure 1; illustration 5) 
and have the ability to differentiate into all three germ layers as well as the germ line;  
 
Endoderm forms, e.g., the stomach, liver, pancreas, urinary bladder, epithelial 
parts of the trachea, lungs and intestines. 
 
Mesoderm forms, e.g., skeleton, skeleton muscles, the dermis of the skin, 
connective tissue, the heart, blood (lymph cells), kidney and spleen. 
 
Ectoderm forms, e.g., the central nervous system (CNS), the lens of the eye, 
the ganglia and nerves, the epidermis, hair and mammary glands.  
 
Germ line forms, e.g., oocytes or sperms which carries the maternal or paternal 
genetic material, having a haploid set of chromosomes. 
 
Unlike totipotent cells, pluripotent cells do not have the ability to form extra embryonic 
tissue such as trophectoderm which gives rise to the placenta. 
 
Multipotent cells or adult SCs are found within already specialized tissues and can 
differentiate into different specialized cell types but are lineage restricted. Hair, skin, 
bone marrow, central nervous system and male germ cells are examples of where 
multipotent SC can be found. 
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1.2.2 Pluripotent Stem Cells 
Already in the 1960´s stem cells from rabbit cleavage-stage embryos could be grown 
and the stem cell story began, developed from the beginnings of In vitro fertilization 
(IVF) research when oocytes were matured and fertilized in vitro4. In Table 1 a 
summary of the most important steps of stem cells research can be found in 
chronological order. 
 
1.2.2.1 In vitro fertilization 
Fertility is the natural capability to give life, and can be measured by the time taken to 
achieve pregnancy. In humans, the prevalence of infertility is high, affecting 10-15 % 
of fertile couples, and infertility is defined as the inability to become pregnant within a 
year without using contraceptives5. The reason for infertility could be cause by either 
female (one-third) or by male factors (one-third). The last third is due to unexplained 
causes. Regardless of the cause of infertility these couples can undergo IVF as a 
treatment in order to conceive children. Fertilized eggs not used in the treatment can be 
donated to stem cell research.  
 
 
 
Chronology  
1962 Systematic collection of mature oocytes from patient’s ovaries 
1962 Rabbit embryo stem cells grown and differentiated in vitro from inner 
cell mass 
1963 Rabbit stem cell lines established 
1965 Human oocytes matured in vitro to metaphase 2 and first polar body 
1967 Cells injected into mouse blastocysts produce mosaic chimaeras 
1968 Rabbit blastocysts sex determined successfully 
1969 Fertilization in vitro of human oocyte matured in vitro 
1970 Mature oocytes aspirated from human follicles after gentle priming of 
patients with gonadotrophines 
1971 Human fertilization and embryo growth in vitro to expanding blastocysts 
1972 Human embryo transfers begin 
1977 Human embryos grown to day 9, with huge embryonic discs trumpeting 
news of stem cells 
1978 Birth of first IVF baby 
1981 First attempt at producing mouse stem cells 
1984 First attempt at producing human stem cells 
1998 First permanent human embryonic stem cell line 
2006 Induction of pluripotent stem cells from mouse fibroblasts using defined 
factors 
2007 Induced pluripotent stem cell lines derived from human somatic cells 
2007 Martin Evans receives the Nobel prize in Physiology or Medicine 
2010 FDA approves first clinical trial using human embryonic stem cells 
2010 Robert G. Edwards receives the Nobel prize in Physiology or Medicine 
2012 Shinya Yamanaka shares the Nobel prize in Physiology or Medicine with 
John Gurdon 
 
Table 1. Human IVF and Stem cell development in chronological order.  
Modified from Edwards R.G 2001, Nature. 
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1.2.2.2 Embryonic Stem Cells and their derivation 
Already in 1981 the first embryonic stem cells (mESCs) were derived from mouse 
blastocyst6 and could be cultured in the same manner as embryonic carcinoma cells on 
mouse embryonic fibroblasts (MEF)7.  
After more than a decade since the derivation of mESCs6 and the primate research8, the 
first human ICM were successfully cultured for a few passages9 and a few years later 
the first permanent hESC line were established10, marking a key historical scientific 
achievement. 
 
hESCs are most often derived from supernumerary blastocysts (5-6 days after 
fertilization), donated from patients undergoing IVF (Figure 1, illustration 5).  
Many different techniques have been used during the years to separate the ICM from 
the trophectoderm cells11, such as immunosurgery12, laser isolation13 whole blastocyst 
culture14 and mechanical isolation, using a small flexible metal needle (0,125 mm in 
diameter). hESCs can be cultured both on MEFs, mitotically inactivated human 
foreskin fibroblast (HFFs)15 or feeder free using various matrices16-22 (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
Regardless if the cells are being cultured using supporting cells or a matrix they can be 
passaged in various ways. Traditionally hESCs, and later hiPSCs, can be passaged 
mechanically using a surgical scalpel, or enzymatically using trypsin-like solutions. 
Regardless of their passaging method the cells usually form colonies, each colony 
consisting of approximately 20 000 SCs. If they are grown on fibroblast the cells tend 
to follow the fibroblast, resulting in a elongated shape (Figure 3A), while cells grown 
on a matrix have a more circular shape (Figure 3B). Typically the morphology of both 
hESC colonies and hiPSC colonies is flat and compact, with sharp edges, and in high 
Figure 2. Human embryonic stem cell derivation and their potential. 5-6 days after fertilization 
the ICM can be isolated and plated on supporting feeder layer or matrix and give rise to a stem cell 
line with self-renewal potential. These cells can give rise to ectodermal cells, mesodermal cells, 
endodermal cells as well as the germline. Illustrated by Emma Nyrell. 
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magnifications it is possible to see that the individual cells have a large nucleus and 
small cytoplasm (Figure 3C). 
To control pluripotency in hESC cultures exogenous basic fibroblast growth factor-2 
(bFGF2) is supplemented to the culture medium. FGF signaling promotes hESC self-
renewal and is involved in blockage of extra-embryonic differentiation23-24. It has also 
been shown that bFGF cooperate with activin signaling through SMAD2/3 to activate 
NANOG expression24-26.  
It has been discussed whether ES cells are trapped in development or if they are simply 
a result of their culture conditions27. By single-cell RNA sequencing of individual 
OCT4-positive or OCT4-negative ES single cells, followed by monitoring the progress 
towards ES cells, signatures of undifferentiated ES cells clearly differ from the cells of 
the ICM. During the transition from ICM to ES cells, the normal development is 
changed and the cells acquire the capacity for unlimited self-renewal and the capacity 
to differentiate towards the three germ layers28. 
 
OCT4, SOX2 and NANOG have been identified as key transcription factors with 
essential roles in early development and they are also required for the propagation of 
undifferentiated SCs in culture29-32. These key transcription factors have been shown to 
occupy promoters for many important developmental regulators in human ES cells33, 
making it possible to activate or turn off genes to reach a certain developmental state of 
a cell, e.g. switching off genes involved in differentiation of pluripotent cells, or the 
other way around, activating genes involved in specific cell types and inactivating 
genes associated with pluripotency.  
 
 
 
 
 
 
1.2.2.3 Induced Pluripotent Stem Cells 
By forced over expression of embryonic transcription factors, most somatic cells in the 
body can be reprogrammed into a pluripotent state. These stem cell-like cells are called 
induced pluripotent stem cells (iPSCs). This was first achieved in mouse adult cells34, 
and later in human cells by two separate research teams35-36. To find the optimal set of 
transcription factors that could reprogram somatic cells into pluripotent cells, twenty-
four candidates of transcriptional regulators were transduced into the host genome 
(MEFs) by retroviral delivery37.The factors were eliminated one by one, and a set of 
four core genes were identified consisting of OCT4, SOX2, KLF4 and c-MYC (known 
as  the “Yamanaka factors”). Almost simultaneously James Thomson and his team also 
Figure 3. Typical hESC colonies. (A) hESC colony cultured on human foreskin fibroblasts, 40 x 
magnification. (B) hESC colony cultured on Matrigel, 40 x magnification. (C) Typical morphology of 
hESC with large nucleus and small cytoplasm, 400 x magnification. Holm, F unpublished. 
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succeeded in the generation of iPSCs but by using a lentiviral system comprising a 
different set of transcription factors, namely OCT4, SOX2, NANOG and LIN2836.  
Similar to ES cells, these cells express genes and surface proteins specific for 
pluripotency, they generate teratomas when injected subcutaneously into immune 
comprised mice as well as contributing to different tissues of developing embryos upon 
blastocyst injection34-35. These characteristics make them an excellent tool to study 
developing human diseases and providing an autologus cell source with potential for 
use in cell-based therapies. iPSCs have been derived from many different somatic cell 
populations, such as neural cells38, melanocytes39, stomach and liver cells40, 
keratinocytes41, lymphocytes42-43 and pancreatic β cells44. This technique has also been 
applied in various species such as rat45-46, monkey47, pig48, dog49 and rabbit50, 
demonstrating that fundamental features of transcriptional network governing 
pluripotency remain conserved during evolution51. 
  
 10 
1.2.3 Differentiation 
If you look closely at the human body, it is clear that not all cells are alike. For 
example, cells that make up our skin are certainly different from cells that make up our 
inner organs. Yet, all of the different cell types in our body are all derived from a 
single, fertilized egg cell and made possible through differentiation, and each of the 
different cells in our body contain the same set of approximately 20 000 genes.  
Differentiation is the process where an unspecialized cell, such as the embryonic stem 
cell, becomes specialized into one of the many cells that make up our body, such as a 
heart, liver or muscle cell. During differentiation, certain lineage-specific genes are 
turned on, or become activated, while other genes are switched off, or inactivated, such 
as OCT4 and NANOG. This process is intricately regulated. As a result, a differentiated 
cell will develop specific structures and acquire qualities to perform certain functions. 
For example, OCT4, NANOG, SOX2 and KLF4 are part of a core pluripotency 
network that serves two main purposes, (1) the repression of genes associated with 
differentiation, and (2) the activation of ESC-specific targets33, 52.  
The suppression of pluripotency factors in pluripotent SCs is associated with the 
recruitment of repressive chromatin modifying complexes, such as the NuRD 
complex53 and the Polycomb complex54, while the activation of pluripotency factors 
may be associated with chromatin remodeling factors, such as the SWI/SNF complex. 
These core factors are expressed in ESCs and turned off when the cells differentiate and 
they are highly enriched for active chromatin marks. The interplay between self-
renewal and differentiation in pluripotent SCs is a direct reflection of the levels of 
active marks such as H3K4me3, and repressive marks such as H3K27me3. 
 
By purposely allowing pluripotent SC to differentiate, both in vitro and in vivo, it is 
possible to verify whether the cells are truly pluripotent, possessing the ability to 
differentiate towards all three germ layers. 
 
1.2.3.1 In vitro differentiation 
By culturing aggregates of pluripotent SCs in suspension without the “anti-
differentiation factor” bFGF cells are allowed to undergo differentiation, forming 
embryoid bodies (EBs). After approximately 3 weeks in culture the cells starts to form 
three-dimensional spheroid structures. Without the bFGF, this spheroid structures are 
capable of responding to similar cues that direct embryo development, forming tissues 
resembling native tissue structures.  
EB formation is often used to spontaneously differentiate cells toward all three germ 
layers, in order to control the pluripotent state of SCs, but can also be used together 
with specific factors for a more specific and directed differentiation. 
 
1.2.3.2 In vivo differentiation 
By injecting pluripotent SCs subcutaneously or beneath the testicular capsule of severe 
immunodeficiency (SCID) mice the SCs will start to form encapsulated tumors, 
teratomas, which contain tissue components of all three germ layers. The teratomas are 
usually harvested within a few weeks after implantation of the SCs and analyzed by 
sectioning and staining.  
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The ability of pluripotent SCs to form these noncancerous tumors is one of their 
defining traits, and instead of originating from a single abnormal cell, they originate 
from a group of normal cells. By comparing gene expression in undifferentiated cells, 
embryoid bodies and teratomas it was found that the gene survivin (BIRC5) seemed to 
contribute to tumor formation55. This gene is located on chromosome 17, which also is 
one of the genomic regions that are found to be amplified when ES cells change in 
culture (culture adaptation) towards being precancerous56-57. 
The possibility for tumor formation of transplanted pluripotent SCs is a major safety 
concern which has to be addressed before using the cells clinically.  
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1.2.4 Molecular mechanisms of pluripotency 
Pluripotency is a complex process established by genome-wide reprogramming during 
mammalian pre-implantation development, where cells are given the ability to give rise 
to all the tissues of the adult body. Pluripotency has been called the transitory state of 
embryonic cells and exists only during a brief window of development. The molecular 
mechanisms that control pluripotency are important for improving our understanding of 
development, and therefore understanding defects in development which may cause 
many diseases. Hopefully this understanding may eventually lead to new therapies.  
Pluripotent SCs have a gene expression program that allows them to self-renew but still 
remain poised to differentiate as a response to developmental cues. 
 
1.2.4.1 Extracellular factors 
In human pluripotent SC cultures, one of the most important extrinsic factor is bFGF2 
which was the first factor found to be crucial for maintaining hESCs in culture, 
resulting in the incorporation of this factor in many chemically defined media to 
improve hESC cultures58.  
bFGF2 acts through surface receptors on pluripotent SCs leading to activation of 
Receptor Tyrosine Kinases (RTKs) ERK1 and ERK2 which mediates signals important 
for pluripotency and self-renewal (Figure 4). Inhibition of this pathway leads to 
differentiation24. The precise biological action of bFGF2 in hESCs is unclear, although 
there is evidence that it maintain SC phenotype rather than promoting proliferation and 
cell death. Another role of bFGF2 is to suppress Bone Morphogenic Protein (BMP) 
signaling and therefore inhibit differentiation59.  
 
Another important factor is Transforming Growth Factor beta (TGF-β). The TGF-β 
super family consists of signaling proteins that mediate a broad range of biological 
effects by binding to cell-surface receptors, including activin and nodal, growth 
differentiation factors (GDFs) and BMPs, all of which are involved in maintaining SC 
state. Activin and nodal, which signal through the same receptors, have been shown to 
suppress the differentiation of hESCs25, 60-61. These two signaling factors together 
activate the transcription factors SMAD2 and/or SMAD3 which binds to the promoter 
of the gene encoding the key pluripotency transcription factor NANOG in hESCs. 
Therefore, blockage of TGF-β results in differentiation. On the other hand, SMAD1, 
SMAD5 and SMAD8 which are activated by BMPs have the opposite effect and inhibit 
NANOG expression by binding to its promoter26 (Figure 4). 
The Wingless-type MMTV integration site family (WNT)-mediated signaling’s main 
effect on hESCs is to enhance proliferation62 and it also allows short-term maintenance 
of hESCs63, while TGF-β and bFGF2 are required for long-term maintenance60, 64. 
 
1.2.4.2 Intracellular factors 
Much effort has been aimed at identifying the genes that are essential for stemness 
(essential characteristics of a stem cell that distinguish it from ordinary cells). In the 
pluripotency network, the most important factors are NANOG, OCT4/POU5F1, KLF4 
and SOX2. These four transcription factors interact and regulate the expression of 
multiple genes33 and have essential roles in early development and are required for the 
propagation of undifferentiated hESCs in culture.  
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To further understand how NANOG, OCT4/POU5F1 and SOX2 control pluripotency 
and self-renewal in pluripotent SCs, a genome-scale location analysis (chromatin 
immunoprecipitation coupled with DNA microarray) were used to identify the target 
genes of all three regulators in vivo33, 52. The results revealed that these three factors co-
occupy the promoters of a large population of genes where many of these target genes 
encode developmentally important homeodomain transcription factors, and that these 
regulators contribute to specialized regulatory circuits in hESCs33.The key concept of 
how the core transcription factors control ESC state is through positive regulation of 
their own promoters, where they form an interconnected auto-regulatory loop. They co-
occupy and activate expression of the genes which are necessary to maintain ESC state, 
while contributing to repression of genes encoding lineage-specific transcription factors 
whose absence keep the cells from undergoing differentiation65. 
 
NANOG is a transcription factor known to be important in early embryogenesis and 
pluripotency31, 66-67 and it has been shown that Nanog null mice die before 
implantation66. It has also been used as one of the factors when reprogramming somatic 
cells towards a pluripotent state, however it does not need to be included as one of the 
essential exogenous factors which could be explained by OCT4/POU5F1 and SOX2 
activation of endogenous NANOG34-35 
OCT4/POU5F1 is a transcription factor which is also is known to play an important 
role in pluripotency29, 33, 68. OCT4/POU5F1 has also been used for reprogramming, 
both alone and together with other transcription factors34-36, 69-71. Mouse embryos 
lacking the Oct3/4 gene do not develop normal ICM, instead they develop cells with a 
trophectodermal fate72. 
The transcription factor SOX2 is indispensible for pluripotency in hESCs73 and Sox2 
null mouse embryos are incapable of forming normal epiblast and therefore they do not 
survive30. Together with both NANOG and OCT4/POU5F1, SOX2 is one of the factors 
used for reprogramming somatic cells towards pluripotency34-36. 
 
Proteins which are associated with the core transcription factors OCT4, NANOG, 
SOX2 and KLF4 include the SWI/SNF complex. This complex of enzymes is found in 
all cells and has ATPase activity, which means it breaks down ATP (the basic unit of 
energy currency). It is involved in chromatin remodeling, where its primary function is 
to aid gene expression. This is achieved by shifting or altering the positions of the 
nucleosomes, resulting in the exposure of DNA allowing e.g. transcription factors to 
bind, and therefore increase transcription.  
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Figure 4. Extrinsic signals affecting self-renewal, differentiation and viability. Signaling mediated 
by members of the TGF-β family, such as TGF-β, activin and nodal, GDFs and BMPs-converges 
mainly on NANOG, which maintains ES cells in an undifferentiated state with the ability to self-renew. 
Signaling activity mediated by the MEK-ERK receptor tyrosine kinase cascade allows self renewal of 
ES cells and maintains their viability (through inhibiting apoptosis and anoikis).In addition, IGF2-
mediated signaling through PI(3)K inhibits ES cells from differentiating into endodermal lineage cells. 
WNT-mediated signaling might affect these cell-fate decisions, but its role is controversial at present. 
Illustrated by Emma Nyrell, Modified from figure 2 Pera, M et al., 2010 Nature.
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1.2.5 Chromatin structure in pluripotent stem cells 
In order to fit into the nucleus, the approximately two meters of DNA that each cell in 
our body contains it is packed into chromatin74. The packing of chromatin is variable, 
with euchromatin representing open, gene rich, transcriptionally active regions. In 
contrast, heterochromatin represents condensed regions with low gene density but high 
levels of repetitive sequences75-76. The nucleosome is the fundamental unit of 
chromatin, acting as spools of which 146 base pairs (bp) of DNA is wrapped around, 
consisting of an octamer of the histones, namely H2A, H2B, H3 and H4, two of each. 
Between two nucleosomes, the histone H1 acts as a linker, which initiates higher-order 
chromatin structures (Figure 5).  
 
In this way, eukaryotic DNA is packed into highly compacted chromatin.  
There are three levels of chromatin organization: 
 
DNA wraps around histone proteins forming nucleosomes; the “beads on a 
string” structure (euchromatin). Euchromatin is less condensed and more 
accessible. 
 
Multiple histones wrap into a 30 nm fiber consisting of nucleosome array in the 
most compact form (heterochromatin). Heterochromatin is highly condensed 
and inaccessible. 
 
Higher-level DNA packaging of the 30 nm fiber into the metaphase 
chromosome (during mitosis and meiosis). 
 
 
 
 
 
 
 
Chromatin undergoes various forms of structural change to alter DNA packing. 
Alteration to the chromatin structure that do not affect the sequence of the genome are 
Figure 5. Schematic illustration of DNA packing. The DNA winded around the eight core 
histones and packed in to the chromosome. Normally each cell in the human body contain 46 
chromosomes, 23 paternal and 23 maternal. Illustrated by Benjamin Tengzelius. 
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called epigenetic modifications, including methylation of DNA, post-translational 
modifications (PTMs) of histones (often referred to as histone marks), histone variants 
incorporated into nucleosomes as well as the action of proteins binding to DNA and 
chromatin remodeling complexes. Also non-coding RNA is involved in epigenetic 
changes through X chromosome inactivation 77. Modifications on specific residues, e.g. 
lysine (K) include acetylation (ac), mono-methylation (me1), di-methylation (me2) and 
tri-methylation (me3), and mono-ubiquitylation (ub1) which modify chromatin 
structure and control the access of various enzymes. Acetylation can result in the 
loosening of the chromatin and lends itself to replication and transcription. Lysine 
acetylation is generally associated with gene expression, whereas lysine methylation 
can lead to either gene activation or repression, depending on the residues involved.   
 
Chromatin structure can be distinguished through a microscope by densely packed 
nucleosomes, heterochromatin, or sparsely packed chromatin, euchromatin.  
The chromatin state of undifferentiated stem cells are being recognized as open and 
hyper dynamic compared to somatic cells, with a progression towards a more compact 
and repressive chromatin structure upon differentiation. 
Heterochromatin is distinguishable molecularly by “repressive” modifications, such as 
H3K9me3 and H3K27me378. 
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1.3 MICROENVIRONMENTAL EFFECTS 
The maintenance of undifferentiated SCs for prolonged periods and the extensive 
cultures of SCs need to meet the needs for clinical use. Genetic and epigenetic changes 
are a direct response to the microenvironment which the cells are exposed to. 
Despite the many common characteristics among cell lines, it is now known that there 
may be large variations between the different cell lines, which could be an effect due to 
the influence the specific cell line is subject to from its microenvironment.  
 
To enable the use of these cells in the future, one major hitch to overcome has been to 
cryopreserve SCs in a manner where they can be stored long term and thawed quickly 
with minimum damage and with minimal impact to the cells pluripotent state. It has 
been challenging to obtain high survival rates after thawing cryopreserved hESC and 
later also iPSCs, which have been of importance due to the rapid development within 
the field suggesting a broad use both in research and therapeutically. Recently there has 
been clear improvements in regard to techniques and media to cryo-store both small 
and large amounts of stem cells and the focus has slowly transferred from sole survival 
of the stem cells to chemically defined and xeno-free cryopreservation systems suitable 
for GMP making the cells transferrable for clinical use. 
Once a suitable protocol exists for preserving cells while awaiting clinical use, another 
issue is how different culture techniques and long term culturing influences and affect 
the cells in regard to their pluripotency, especially gene expression as well as 
acetylation and methylation of the histones, when inhibiting the Rho-associated coiled-
coil kinase (ROCK) signaling pathway, which is a pathway involved in many cellular 
processes, one of them is apoptosis. This led to the interest of inhibiting ROCK in cell 
cultures to increase the survival rates when the cells are dissociated from each other.  
To identify valid hESC lines and hiPSC lines to further clinical use it is important to 
investigate how shift or altering of the position of the nucleosomes so that the DNA is 
exposed allowing e.g. transcription factors to bind and therefore increase transcription 
which can affect the characteristics of the cells, and if it correlates to the gene 
expression of the same factors. 
Another concern when keeping cells in culture for many passages is that it might result 
in the selection of cells with genetic changes which often results in growth advantages 
by acquired mutations. These mutations, called copy number variations (CNVs) may 
range from about 1 kilo base (1,000 nucleotide bases) to several mega bases in size. 
 
The microenvironmental effects on pluripotent SCs, ranging from preserving cells in an 
effective “stand-by” position ready to be used for patients, to the effect on the cells due 
to culture techniques, long-term culture and differentiation. This and many other 
aspects of pluripotent SCs have to be addressed before using these cells clinically. 
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1.3.1 Cryopreservation 
Cryopreservation is the process where cells or whole tissues are preserved by cooling to 
sub-zero temperatures, -196 °C, which is the boiling point of liquid nitrogen (N2). 
These low temperatures are effectively stopping any biological activities within a cell.  
Two techniques are so far available for cryopreservation of pluripotent SCs: 
vitrification and slow freezing-rapid thawing. The most challenging and the mostly 
performed technique is vitrification using open pulled straws, in which a small amount 
of SCs can be frozen using high concentration of cryoprotectants in order to quickly 
obtain a glass-like structure79-80. During slow freezing-rapid thawing larger amounts of 
SCs can be frozen using lower concentrations of cryoprotectants, in cryo vials. 
 
To avoid permanent damage to cells, different cryoprotectant agents are being used, 
and are presumed to provide an indefinite durability to cells in sub-zero temperatures.  
Many other biological fields have been using cryo-storage as a possibility to transfer 
and long term store valuable material, and it became clear that this knowledge could be 
used also for SCs.  
However, living tissues or cells mostly consist of water (H2O), and when being cooled 
to below the freezing point water molecules gather together and form ice crystals, 
damaging the cells by dehydration (migration of water out of the cells) as ice is formed 
between them.  
The ice formation begins in the intracellular spaces, where the osmotic pressure of the 
ice is lower than the osmotic pressure of the solute water in the surrounding cells and as 
heat is removed at the freezing point of the solutions, ice crystals grow between the 
cells, extracting water from them81 (Figure 6).  
As ice crystals grow the volume of the cells shrink, and the cells are crushed between 
the ice crystals. When the cells shrink, the ice also squeezes the solutes inside the cells 
and concentrates it in the remaining water, increasing the intracellular ionic strength 
and interfering with the organization of the proteins and other intracellular structures. 
This eventually lead to the solute concentration inside the cells reaching the eutectic 
state (mixture of substances having a minimal freezing point) and freezes82 (Figure 6). 
The final stage of frozen cells is pure ice in the former extracellular spaces, and inside 
the cell membranes a mixture of concentrated cellular components in ice and bound 
water. Without cryoprotectants, this process would not be reversible. 
By the addition of a cryoprotectant to the solution it can help prevent water molecules 
from gathering together to form ice, this way, the molecules start moving slower and 
slower as they are cooled, instead of freezing altogether. When the temperature 
reaching below -100 °C the molecules become locked in place and a solid is formed. 
Water that becomes solid without freezing is called “vitrified”.  
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Cryopreserving pluripotent SCs has resulted in low survival rates and loss of SC 
identity such as proliferation, differentiation potential and also pluripotency, an 
important feature of ESC.  
The results did not improve despite that all the other fields in SC research quickly 
moved forward. Just as having optimized clinical grade cultures, it is essential to obtain 
efficient clinical grade cryopreservation systems for hESCs and hiPSCs, which led to a 
combined effort within the cryo-storage field and which progressed during the 20th 
century. 
Since the beginning, cryopreservation of these cells included culture medium 
containing 10% dimethylsulfoxide (DMSO) as the only cryoprotectant (permeable) 
where large amount of cells have been cryo stored in one vial. This method has been 
improved during the years using various solutions83.  
 
Both hESCs and iPSCs are highly sensitive to cryo-injury caused by cryopreservation 
which has limited its utility and thus led to extensive studies recent years80, 83-88. 
 
Figure 6. Cryopreservation. Between approx. -5 °C and -15 C°, ice forms in the external medium, 
however the cell contents remain unfrozen because the plasma membrane blocks the growth of ice 
crystals into the cytoplasm. The cooled water in the cells has a greater chemical potential than the 
water in the partly frozen solution outside. The difference in potential causes water to flow out of the 
cell osmotically and freezes externally. When no cryoprotectant is added to the cells, the water 
molecules gather and form growing ice crystals. First ice forms outside the cells, which causes the 
cells to dehydrate and shrink, leaving the cells to be squashed between ice crystals. When adding a 
permeating cryoprotectant like DMSO, water molecules surrounding the cells move slower and 
slower, and finally lock in place to form a solid, with less damage to the cells. By adding both a 
permeating and non-permeating cryoprotectant, it is possible to control ice crystalization at both 
extracellular and intracellular level.  
 20 
By using a medium that is completely serum and animal substance free, containing 
DMSO, anhydrous dextrose and a polymer as cryoprotectant instead of using only one 
cryoprotectant, DMSO, the survival rates have increased. The use of combinations of 
cryoprotectants in hESC banking has not been reported earlier in the SC biology field 
and this procedure can be conducted without dedicated instrumentation which will 
facilitate its use. 
 
1.3.1.1 Cryopreservation using STEM-CELLBANKER 
STEM-CELLBANKER is a defined cryopreservation medium which contains 10% 
DMSO, glucose and a high polymer working as a secondary extracellular 
cryoprotectant, as well as NaCl, KCl, Na2HPO4, HK2PO4, NaHCO3 as pH adjustors to 
maintain the cell function. These ingredients are all dissolved in phosphate-buffered 
saline (PBS).  
For optimal dehydration and minimal ice crystal formation, the medium contains both 
permeating and non-permeating cryoprotectants. The cells can be frozen directly at -80 
ºC, without a programmed freezer. After 24 hours the cells should be transferred to N2 
tanks. 
This system using a defined freezing–thawing system offers an excellent simple option 
for banking of hESCs and iPSCs, allowing large cell numbers to be frozen in one vial, 
resulting in outstanding cell survival after freezing. When comparing this novel method 
with the standard method (10% DMSO), the cells had a high viability (90–96%) 
without any impact on proliferation and differentiation, compared with the standard 
freezing procedure where viability was much lower (49%)89. 
 
1.3.1.2 Thawing using CELLOTION 
When a cell has avoided lethal damage during cooling to low sub zero temperatures, 
they must still survive series of physical-chemical challenges associated with 
warming/thawing. The rate of thawing can exert effects on survival which is dependent 
on whether the prior rate of cooling has induced intracellular damage or dehydration. If 
the cells have not been killed outright, the ice crystals tend to be small, and therefore 
fuse to form larger crystals during thawing, the process is called re-crystalization and is 
often damaging to the cells if the crystals are too big from the beginning, resulting in 
the cells breaking.  
CELLOTIONTM is a chemically defined washing solution containing NaCl used when 
cells frozen with STEM-CELLBANKER are being thawed. It is a unique solution free 
from serum, proteins and sugars, which enables cells to sink to the bottom when being 
centrifuged and therefore minimizes the cells lost during washing steps.  
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1.3.2 Passaging human pluripotent stem cells 
Pluripotent SCs can be expanded essentially for an indefinite period in culture and kept 
in a pluripotent state. In order to keep the cells from undergoing spontaneous 
differentiation they need to be passaged every fourth to seventh day, meaning that 
colonies are divided into smaller pieces and transferred to fresh culture dishes. 
Passaging of pluripotent stem cells can be compared to manual “cutting and pasting” of 
colonies. Various passaging techniques for hESCs and hiPSCs have been established15, 
90-94 to facilitate their use, for example mechanical passaging using a surgical scalpel or 
cell scraper16, and enzymatical passaging using trypsin-like solutions to dissociate cells 
into single cell suspensions. 
 
1.3.2.1 Mechanical passaging 
Mechanical passaging is usually performed either with a surgical scalpel, or a cell 
scraper16. This method is one of the most widespread methods for passaging of 
pluripotent SCs. With this technique undifferentiated SC colonies are cut into smaller 
pieces, separated based on their morphology, making it possible to avoid any 
differentiated cells. This manual procedure is very laborious and time-consuming, but 
most importantly it is difficult to obtain high enough numbers of cells needed for many 
of the techniques used in research.   
 
1.3.2.2 Enzymatical passaging 
Enzymatical passaging techniques using solutions such as TrypLE Select/Express95, 
Trypsin-EDTA96-98 or Accutase99 to dissociate the cells into single cells have been 
widely used. Enzymatical passaging give rise to larger amount of cells in a shorter time 
frame, compared to mechanical passaging95. However, pluripotent SC have shown to 
lose their cell-cell interactions when being dissociated from each other, resulting in 
higher cell death during passaging. Groups of cells communicate with each other by 
cell-cell interaction through the Notch signaling pathway. The Notch protein has a large 
extracellular domain and a smaller intracellular domain, and ligand proteins bind to the 
extracellular domain and after proteolytic cleavage the intracellular domain is released 
and enters the nucleus where it engages other DNA binding proteins and can modify 
gene expression100. Almost all ligands are trans-membrane proteins; therefore the 
receptor can only be triggered through cell-cell contact making it possible for groups of 
cells to influence one another to make large structures. 
To overcome these problems which occur when cells lose their cell-cell interaction, 
using a ROCK inhibitor (ROCKi), Y-27632 was neccessary101. 
 
1.3.2.3 Rho-associated coiled-coil kinase (ROCK) 
Rho is a member of the superfamily Ras and act through a number of different proteins, 
most importantly ROCK. Activation of the Rho pathway occurs when G-protein-
coupled receptors (GPCR), growth factor receptors (GFR) and integral membrane 
proteins (e.g. integrins) transport signals into the cytoplasm through the membrane. In 
the membrane GDP is exchanged for GTP in order to be activated, this process is 
catalyzed by RhoGEFs. GTP-bound Rho activates the kinase domain of ROCK by 
binding to it, allowing ROCK to regulate effectors located downstream, including 
myosin light chain (MLC) and LIM (Figure 7). 
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To inhibit the signaling cascade, Rho-GAPs enhance the conversion of GTP-GDP and 
thereby inactivate Rho and the pathway, the alternation between the active and inactive 
state is regulated by guanine exchange factors (GEFs) and GTPase-activation proteins 
(GAPs). The ability of Rho to alternate between GDP-bound inactive state and a GTP-
bound active state allows Rho to control downstream signal transduction events. 
 
SCs undergo high cell death when they are dissociated from each other which are 
believed to be due to the loss of their cell-cell interactions. To solve this issue ROCKi, 
has been widely used101, where it is added to culture prior to passaging, as well as the 
first 24 hours after passaging. 
 
 
 
 
 
 
 
 
 
  
Figure 7 Rho/ROCK signaling cascade. GPCR, GFR or integrins can activate the Rho pathway. 
When the signal for activation reaches Rho, it is transported to the plasma membrane where it is 
activated by exchange of GDP to GTP, catalyzed by RhoGEFs. Rho with the GTP binds to and 
activates the kinase domain of ROCK allowing ROCK to regulate effectors such as MLC and LIM 
kinase. This signaling cascade can be inhibited by RhoGAPs convert GTP-GDP and thereby 
inactivating Rho and its pathway. Illustrated by Emma Nyrell.
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1.3.3 Histone acetylation and methylation 
The N-terminal tails of histones extend outwards from the nucleosome particle (Figure 
8), and are the sites for regulatory modification. Histone methylation and acetylation 
typically takes place on arginine or lysine amino acid residues in the protein sequence. 
Histones that for example are methylated on certain residues can act epigenetically to 
repress or activate gene expression. Histone modifications that are associated with 
active transcription such as acetylation of histone H3 and histone H4 and di-and 
trimethylation of lysine 4 on histone 3, are commonly referred to as euchromatin 
marks, whereas modifications that are associated with inactive genes, such as 
methylation on lysine 9 and lysine 27 on histone H3 (H3K9, H3K27) are referred to as 
heterochromatin marks.  
 
 
 
 
 
 
 
 
 
Aceylation of histones has two well-characterized functions; (1) causes local changes in 
the charge between DNA and the histone proteins that disrupt the chromatin structure. 
The addition of acetyl groups neutralizes the positive lysine residues and therefore 
reduces the histone interaction with DNA which is negatively charged. (2) Serves as 
platforms to bind proteins. 
Histone acetylation is mediated by histone acetyltransferase complexes (HATs)102. A 
rule of thumb is that acetylation of histones leads to an open and transcriptionally 
permissive chromatin, and increased acetylation of histones has been correlated with 
increased gene expression103-104.   
Figure 8. Schematic representation of the N-terminal tails and C-terminal tails on histone H2A, 
H2B, H3 and H4. Posttranslational modifications of histones include acetylation (A), methylation 
(M) and phosphorylation (P). Some lysine residues can be either acetylated or methylated. 
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Histone acetylation in gene promoters is reversible which can be achieved by the 
recruitment of histone deacetylase (HDAC) that remove the acetyl groups, limiting 
access to DNA and therefore repressing transcription103-104.  
Unlike acetylation, methylation has no electrostatic activity. Instead it alters the 
properties of the nucleosomes and affects the interaction with proteins. There are three 
forms of histone methylation, and it is the modification of certain amino acids on the 
histone proteins, caused by the addition of one (mono), two (di) or three (tri) 
methylgroups. This leads to transcriptional activation or repression of genes.  
 
1.3.3.1 Chromatin remodeling complex 
The ATP-dependent nucleosome remodeling complex SWI/SNF, was the first 
chromatin remodeling proteins to be identified in two independent screens of mutations 
affecting mating-type switching and growth on sucrose, and the name SWI/SNF comes 
from switching defective or sucrose nonfermenting105-106. 
SWI/SNF is recruited by transcription factors and modified histones to the promoters of 
genes, where they enhance or reduce the access of transcriptional components to DNA 
sequences with resulting positive or negative effects on gene activity. 
BRG1, is the catalytic subunit of SWI/SNF and have been shown to interact with γ-
H2AX nucleosomes by interacting with acetylated histone H4. Histone H4 acetylation 
is required for the binding of BRG1 to γ-H2AX nucleosomes. 
 
1.3.3.2 Double-strand break 
Double-strand breaks (DSBs) are the most challenging lesions to repair, because they 
physically cleave the DNA strand. They arise through both replication errors and 
exogenous events such as exposure to ionization radiation. The mechanism of DSB 
repair is the phosphorylation of histone H2AC (γ-H2AX) and loading of DNA repair 
proteins onto the chromatin adjacent to the DSB. The open relaxed chromatin structure 
is created through the coupled action of SWI/SNF ATPase and histone acetylation by 
HATs 
For a number of intracellular processes, such as DSB repair, it is necessary for proteins 
to access the chromosomal DNA. This is regulated by two general chromatin modifier 
mechanisms, including histone modification and alteration of the nucleosomal 
position107.   
SWI/SNF (among other chromatin complexes) has been shown to be recruited to a 
DSB in such a way to facilitate DNA repair and/or modulate checkpoint activation108. 
Mammalian SWI/SNF has been shown to target the chromatin at DSB sites and 
facilitate DNA repair109.  
 
Acetylation of histones located at DSB sites by HATs is a critical chromatin 
modification required for DSB repair. In particular, the N-terminal lysine residues of 
Histone H3 and H4 are acetylated during DSBs. In addition to HATs, SWI/SNF 
chromatin remodeling complexes are recruited to DSBs. ChIP analysis showed that 
DSB-induced acetylation of lysine 8 and lysine 12 within histone H4 occurs in 
mammalian cells108. 
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1.3.4 Culture adaptation 
The value of hESCs and hiPSCs in research and therapeutic applications highly relies 
on their genomic integrity and stability. The moment the hESCs are transferred to a 
culture dish they are subject to new influences from their new environmental conditions 
and the stability of the cells during long term culture cannot fully be guaranteed57. And 
even if differences between individual DNA sequences provide the basis for human 
genetic variability, forms of genetic variations such as SNPs, insertions/duplications, 
deletions and inversions/translocations may provide changes in hESCs and hiPSCs that 
favor cells with characteristics which are not optimal for further use. 
Extensive cultures of stem cells can select for cells with genetic changes. These 
acquired mutations often result in growth advantages, called culture adaptation. By 
using karyotypic analysis these changes have been detected and often involve non-
random gains of various chromosomes or fragments of chromosomes110-113.  
These culture adaptations that leads to growth advantages in pluripotent SCs occurs as 
a successive, selective increase of mutations114. It has been shown that there is no safe 
cut-off point when hESC lines start to pick up chromosomal abnormalities, and even 
changes that are too small to be detected by G-banding can lead to growth 
advantages115. DNA-sequence variations can occur in our genome and are called 
single-nucleotid polymorphisms (SNP). This occurs when two sequences of DNA 
fragments from different individuals contains a difference in one single nucleotide, for 
example AAGCCTA to AAGCTTA. 
Both small and large mutation can take place in low passages, while some hESC lines 
are karyotypically normal after hundreds of passages. 
 
1.3.4.1 Chromosomal stability and instability 
hESCs have been cultured for extended periods, while retaining a diploid karyotype, 
however they are typically aneuploid with distinct chromosomal abnormalities. Up 
until recently, the genome of pluripotent SCs has been characterized mainly by G-
banding metaphase karyotyping, a technique that cover relatively low resolution of 
mutations from 2-10 Mb. 
Chromosomal instability of pluripotent cells is a major obstacle for a safe clinical usage 
of these cells, and since one of the characteristics of SCs is to adapt to alternative fates 
(self-renewal, differentiation or death). It might not be surprising that the cells kept in a 
pluripotent state may favor variants that enhance the probability to self-renew through 
selection116 and it is known that almost all hESC lines suffer from mutations as a result 
of extended cultures as a response to its microenvironment117. Many chromosomal 
alterations have been identified, but the most common mutations, known to be a result 
of the phenomena culture adaptation, has been narrowed down through several studies 
to chromosomes 12, 17, 20 and X56-57, 110-111, 113, 118-121.  Extra copies of fragments of 
these specific chromosomes might drive the cells to an increased exposure of one or 
several genes that promote self-renewal56. 
 
There are variations between human populations, so a SNP allele that is common in one 
geographical or ethnic group may be more unusual in another. This was for example 
used when the International Stem Cell initiative analyzed 125 hESC lines and 11 hiPSC 
lines from 38 laboratories worldwide and could reveal, by the use of SNP arrays, that 
the cell lines included represented most of our major ethnic groups (Figure 9). 112 cell 
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lines passed the quality control criteria and were further analyzed to determine whether 
specific structural variants could be found in particular cell lines and could be narrowed 
down to the population that they were derived from, or if the variants were common to 
all hESC lines with no ethnical correlation. By using an ethnically diverse set of 
reference samples it was possible to cluster the cell lines to their ethnic origin, and it 
was found that the most commonly cited hESC lines originated from northern, 
northwestern and central Europe, Han Chinese, Indian and Middle Eastern populations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
To further demonstrate the impact of long term culture of pluripotent SCs, ISCI found a 
structural variant gain within chromosome 20 in 22 of the analyzed cell lines, which 
were karyotypically normal. The gain was within the minimal amplicon 20q11.2.  
When comparing the cell lines in early and late passage, there were five cells lines 
where this gain could be detected in both low and high passages, but 17 of the 22 cell 
lines gained the structural variant in the late passage, demonstrating that the gain may 
be a response of long term culture, resulting in a positive selective growth advantage56 
Figure 9. Population structure of the human ES cell lines analyzed. Principal component (PC) analyses 
were conducted on the entire final merged data set. PC1 and PC2 are plotted on the y and x axes, 
respectively. (a) The overall distribution of the human ES cell lines studied compared to the major ethnic 
groups identified in the HapMap study (REF!), the human genome diversity panel (HGDP) and the Pan-
Asian SNP initiative (REF). (b-d) The cell lines were further subdivided to show their relationships to 
European (b), East Asia and Indian (c) and Middle East-European-Central South Asian populations (d).  
Amps, K et al., Nat Biotechnol 2011 Nov 27;29(12):1132-44. Figure was reproduced with permission from 
publisher. 
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(Figure 10). The least difference between low and high passage number in the same 
cell lines where this gain was found only in late passage, was 22 passages difference. 
 
 
 
 
 
 
  
Figure 10. Copy number variation occurrence in human ES cell lines during prolonged passage. (a) 
20q11.21 gain. The region on chromosome 20 frequently found to experience gain over extended 
human ES cell culture is indicated by the red boxed region in the chromosome ideogram. Also 
shown are the B allele frequency and logR ratio plots representing instances of one of the longest 
and one of the shortest 20q11.21 structural variants. (b) Length representation of all individual 
occurrences of gains in the 20q11.21 region. Samples from which the structural variants where 
derived are indicated on the left-hand column. The invariant 5´ region and the variable 3´ positions 
are indicated. Positions of the genes outside the minimal amplicon that show greater than 20 RPKM 
level of expression in human ES cells are shown (RPKM = number of reads that map per kilobase of 
exon model per million mapped reads of each gene). (c) Expression, Refseq gene, and regulation 
tracks in the minimal amplicon. Positive and negative strand mRNA-Seq data from H1 human ES 
cells indicating polyA RNA transcripts expressed within the minimal amplicon region 
(chr20:29,267,954-29,853,264) are shown together with H1 human ES cell ChIP-Seq data of histone 
modifications considered universal predictors of enhancer and promoter activity. (d) Comparison of 
expression levels of three genes (HM13, ID1, BCL2L1) contained within the identified minimal 
20q11.2 amplicon between early- (normal) and late-passage (20q11.2 CNV carrying) samples. 
MM01 and FF02 are genetically identical sub-lines from two separate laboratories, MM01 has no 
amplification at 20q11.2, whereas FF02 possesses a copy number change at 20q11.2 that includes 
the identified minimal amplicon (b). Amps, K et al., Nat Biotechnol 2011 Nov 27;29(12):1132-44. 
Figure was reproduced with permission from publisher. 
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1.3.4.2 DNA copy number variations 
Ideally hESCs should preserve their genomic integrity while in culture to avoid 
abnormal development or tumorigenesis. DNA copy-number variations (CNVs) are 
alterations in DNA in the genome, and it contrasts with SNPs which affect only one 
single nucleotid base. These alterations may be inherited or caused by de novo 
mutations. When CNVs have occurred, larger regions of DNA have been deleted or 
duplicated, resulting in abnormal numbers of copies of one or more sections of DNA. 
CNVs can be a result of replication stress and the repair of DSBs by NHEJ. They also 
tend to cluster in regions with complex architecture such as fragile sites, subtelomeric 
regions and centromeres122.   
CNVs include amplifications and deletions that can range between a few kb up to 1 Mb 
and can therefore be studied by using e.g. SNP-arrays (Affymetrix SNP 6.0 array). The 
SNP-array provides copy number estimate for more than 1.8 million markers on a 
single array. The low resolution of karyotyping cannot accurately determine most 
CNVs, which is estimated to involve 10-20% of the genome, due to the large mutation 
coverage. The degree of mosaicism found in samples must be determined by other 
methods, such as fluorescent in situ hybridization (FISH).  
When using interphase FISH it is possible to detect X chromosome aberrations and the 
Y chromosome by using DNA probes specific for the X centromere and the SHOX 
gene on Xp/Yp. The SHOX gene is a homeobox gene and is important in development 
and was first identified during the search for short stature in women with Turner 
syndrome, a syndrome defined by the loss of genetic material from the X chromosome 
or loss of one entire X chromosome (46:X). By studying the SHOX gene it is possible 
to disclose extra chromosomal material on the X chromosome, which is known to be 
involved in culture adaptation. 
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1.4 THERAPEUTIC POTENTIAL OF PLURIPOTENT STEM CELLS 
Both hESCs and hiPSCs hold enormous potential for revolutionizing current medical 
understanding and practice, and these cells have for many years been studied by 
researchers who have been exploring their unique capabilities. Not only are these cells 
an exciting research tool to probe mammalian development or use as a disease model, 
they also have a future in custom-tailored cell therapy51.  
Pluripotent SCs provide a chance to obtain a renewable source of healthy cells and 
tissues and they have a vast potential to treat a wide range of diseases, namely because 
they give rise to all cells within the human body. Despite the success and fast progress 
in research using both hESCs and hiPSCs, these cells are not yet ready for transplanting 
into patients. The main issue for using these cells therapeutically is the safety concerns, 
one of them being that both hESCs and hiPSC tend to form teratomas (encapsulating 
tumor tissue components resembling normal derivation of the three germ layers) when 
transplanted, and the current differentiation protocols cannot eliminate residual 
undifferentiated cells123. 
However, a key advantage of iPSCs is the possibility to use the patient’s own somatic 
cells for reprogramming, an approach where rejection of the graft could possibly be 
avoided. But to date, there are still hurdles to overcome, such as the methods used for 
reprogramming.  
There have been promising reports in mice were iPSCs have been used to treat genetic 
disorders. It has for example been shown that iPSCs can be used in the treatment of 
Sickle cell anemia, where the disease causing mutation was repaired by gene targeting 
and the progenitors were transplanted back into the mice and the healthy cells started to 
produce normal red blood cells124. 
Drug research is another area that pluripotent SCs may prove useful. Animals are a 
commonly used model to assess the safety and use of drugs. Instead of initially testing 
drugs on animals, they can be evaluated though testing on cells grown from pluripotent 
SCs. Those drugs that appear tolerant and safe can then progress to testing on animals, 
and finally humans.  
 
Even if differences among hESCs and hiPSCs shown by others as well as discussed in 
this thesis, such as passage number, viral integration, culture conditions and line-to-line 
variations influence the epigenetic and functional properties of these cells, it is, at this 
point, still important to keep studying these two types of pluripotent SCs in parallel.  
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2 AIMS OF THE THESIS 
 
General aim 
 
The overall aim of the work presented in this thesis was to investigate effects on 
pluripotent stem cells caused by microenvironmental influences, such as 
cryopreservation, passaging techniques and culture adaptation.  
 
Specific aims listed according to each paper: 
 
Study I 
To evaluate a chemically defined xeno-free cryopreservation system for hESC 
lines and hiPSC lines, and its effect on the gene expression, karyotype and 
proliferation caused by cryopreservation and thawing. 
  
Study II 
To evaluate the effects on morphology and gene expression in correlation with 
epigenetic marks due to different techniques when passaging hESCs 
 
Study III 
To investigate putative correlations in hESC and hiPSC lines between gene 
expression and SWI/SNF complex related histone acetylation on lysine 8 and 
12 on H4 on the promoter region of genes associated with pluripotency.  
 
Study IV 
To investigate chromosomal stability of three hESC lines. We compared in vivo 
differentiated pluripotent SCs with in vitro differentiated SCs, using high-
resolution array to study DNA-copy number variations and FISH. 
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3 MATERIALS AND METHODS 
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his section gives a brief overview of a few of the methods used to obtain the 
results presented in this thesis. It mainly focuses on derivation and culture of 
pluripotent SCs.  
The ethics that is necessary to conduct research on SCs derived from fertilized eggs 
will be discussed, and what motivate the donation of some embryos for research instead 
of using them for infertility treatment.  
Some of the techniques used to characterize the pluripotent SCs, such as gene 
expression and chromatin immunoprecipitation will be described briefly.  
More detailed protocols, such as concentrations, primer sequences and other in-depth 
details can be found in the materials and methods section of the included studies. 
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3.1 DERIVATION OF HUMAN EMBRYONIC STEM CELLS 
Fertilization of oocytes and embryo culture is performed by embryologists at the 
Fertility Unit at Karolinska University Hospital.  
Before using the fertilized egg for treatment of infertility all embryos undergo an 
evaluation of their quality following a modified scoring system125. Briefly, a maximal 
score of 3.5 is given to embryos where no factor that reduced the embryo quality is 
observed. The score is reduced in increment of 0.5 for various non-optimal variations 
found in the morphology of the embryo, such as non-ideal numbers of blastomeres or 
non-spherical blastomeres, presence of more than 10% fragmentation, unevenness of 
the cell membrane, cytoplasmic abnormalities e.g.  
Embryos scoring 3.0-3.5 are regarded as top-quality embryos and are always used in 
first hand for the couples. A score of 2.5 is considered good quality and 4-8-cell 
embryos with a score of at least 2.0 are considered suitable for cryopreservation. 
Embryos with lower scores can be donated to research.  
All embryos with a score of 2.0 or more are stored in liquid nitrogen in case of any 
sibling treatment. After storing cryopreserved embryos for five years, all patients get to 
decide whether the embryos should be discarded or donated for research if more 
children are not desirable. This make it possible to derive cell lines from embryos with 
better quality, however a correlation between embryo morphology and successes rate in 
deriving new cell lines have not been detected126. 
A high proportion, 92 % of all couples that went through infertility treatment in 
Sweden, preferred donation their supernumerary embryos to stem cell research instead 
of discarding them127. 
 
3.1.1 Isolation of inner cell mass 
Isolation of the ICM is mostly performed using two different methods, immunosurgery 
or mechanical isolation. When performing immunosurgery the zona pellucid is first 
removed by using 0.4% pronase followed by removing the trophetoderm using rabbit 
anti-human whole serum and guinea pig complement12.  
Mechanical isolation of the ICM is performed by using two small flexible metal 
needles with a diameter of 0.125 mm. One needle is used to hold the blastocyst, and the 
other to open the zona pellucida and remove the ICM from the trophectodermal cells11. 
The isolated ICM grow on hffs for 12-15 days before the first passage to new feeder 
cells or matrix.  
 
3.1.2 Ethics 
To derive and establish hESC lines, ethical approval from the Ethics Committee of 
Karolinska Institutet has been obtained. Donated supernumerary embryos are used for 
derivation, donated from couples undergoing IVF treatment at the Fertility Unit at 
Karolinska University Hospital, Huddinge, Sweden. To donate embryos, both parents 
need to sign an informed consent form after receiving both written and oral 
information. Only embryos that are not used in the treatment of infertility can be 
donated for research. Fertilization of eggs is not allowed to obtain embryos solely for 
research. No reimbursement is paid to the couples.  
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3.2 CULTURE AND CHARACTERIZATION OF PLURIPOTENT STEM 
CELLS 
 
3.2.1 Culture medium 
At Karolinska Institutet the medium used for derivation and culture of pluripotent SCs 
consists of Knockout Dulbecco’s Modified Eagle’s basal Medium (DMEM) 
supplemented with 20% knockout serum replacement (SR), 2 mM glutamax, 0.5 % 
penicillin-streptomycin (PEST), 1 % non-essential amino acids, 0.5 mM 2-
mercaptoethanol and 8 ng/ml bFGF. The media are changed every day. 
 
mTeSR1 is a commercially available culture medium that is used when cells are 
cultured feeder-free on a matrix called Matrigel, according to manufacturers 
describtion18, 128.  
 
3.2.2 Feeder cells 
Commercially available hff’s are used as feeder cells15. They have been mitotically 
inactivated by irradiation (40 Gy). 
The medium for the fibroblasts consist of Iscove’s modified Dulbecco’s Medium 
(IMDM) supplemented with 10 % fetal bovine serum (FBS) and 0.5 % PEST. The day 
after plating irradiated fibroblast the medium is changed to a medium supplemented 
with SR instead of FBS. Three days after plating new irradiated fibroblasts they are 
ready to be used for the culture of pluripotent SCs. Before transfer passaged SCs to 
plates the fibroblast medium is changed to the medium based on DMEM (described 
above).  
 
3.2.3 Extracellular matrix coating 
Plates coated with Matrigel (BD Biosciences, Bedford, MA) are prepared according to 
the manufacturers recommendations by diluting one aliquot of Matrigel in 25 ml 
DMEM/F12 (Stem Cell Technologies). Coated plates are incubated in room 
temperature followed by either storage in 4 °C, or a second incubation of 1 hour prior 
to use in 37 °C. Excess Matrigel is removed just before adding pluripotent SCs.  
 
3.2.4 Passaging 
The different passaging techniques have been discussed in the introduction part. 
 
3.2.5 Karyotyping 
Karyotyping is carried out using the G-banding technique. Cells are treated with 0.1 
µg/ml colcemid KaryoMAX to stop the cell cycle in metaphase. The colcemid treated 
cells is removed by enzymatical passaging and centrifuged at 1,300 revolutions per 
minute (rpm) for 7 minutes. The centrifuged cells are re-suspended with pre-warmed 
hypotonic solution (0.0375 M KCl) and incubated in 37 °C for 10 minutes. After the 
incubation the cells is re-suspended in fixative composed of methanol and acetic acid 
(3:1). Metaphase spreads are prepared on glas slides, G-banded by brief exposure to 
trypsin and stained with 4:1 Gurr’s/Leishmann’s stain. A minimum of 10 metaphases 
are analyzed. 
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3.2.6 Embryoid body formation 
To form EBs, pluripotent SCs are cultured as aggregates in suspension without bFGF. 
After 3 weeks in culture the cells have formed spheroid balls containing tissues 
originating from the three germ layers. This is demonstrated by RT-qPCR using 
markers specific for genes within the germ layers. The EBs can also be sectioned and 
stained by immunohistochemestry using antibodies specific for antigens on the surface, 
or nuclear staining can be performed. 
 
3.2.7 Teratoma formation 
Pluripotent SCs are harvested from culture plates either mechanically or enzymatically. 
The cells are washed with PBS and re-suspended with a small amount of culture 
medium. The cell suspension is implanted beneath the testicular capsule of a young (7-
week-old) beige SCID mouse (C.B.-17/GbmsTac-scid-bgDF N7, M&B, Ry, Denmark). 
The teratoma growth is monitored by weekly palpation and the mouse is sacrificed by 
cervical dislocation after 8 weeks. The presence of tissue components of all three germ 
layers are analyzed from stained sections129.  
 
All animal experiments are performed at the infection-free animal facility of Karolinska 
University Hospital, Huddinge, Sweden, in accordance with Ethics committee 
approval.  
 
3.2.8 Live-dead assay 
The ratio between live and dead cells can be assessed by using a calcein-esterase based 
live-dead assay (Molecular Probes, Eugene, USA). Membrane-permeable calcein is 
cleaved by esterases in live cells to yield cytoplasmic green fluorescence, and 
membrane impairment ethidium homodimer-1 labels nucleic acids of membrane-
comprised cells with red fluorescence. The ratio between red and green cells can be 
seen and calculated using a fluorescence microscope.  
 
3.2.9 RT-qPCR 
Total RNA from pluripotent SCs are isolated by using the commercially available 
Qiagen RNeasy kit, following the manufacturer’s instructions. The concentration of the 
RNA is quantified spectrophotometrically at 260/280 nm. 
To obtain first-strand complementary DNA (cDNA) the RNA is reverse transcribed 
using the enzyme reverse transcriptase (RT). The single strand cDNA was then used as 
a template for PCR amplification. The TaqMan protocol utilizes a probe which has a 
reporter dye in the 5’ end and a quencher in the 3’ end. While the probe is intact, the 
reporter dye will be quenched (Figure 11). The probe is specifically design to anneal 
downstream of one of the primer start sites and when reverse transcription starts it will 
break up the probe and release the reporter dye. This is repeated every cycle and thus 
the reporter signal is proportional with the amplified product. This method only detects 
specific amplification products. The SYBR Green protocol is based on small 
fluorescent molecules that can bind to any double stranded DNA products, such as 
primer dimmers. It is not dependent on a specifically designed probe for each reaction 
which reduces the running costs. For primer or probe sequences see materials and 
methods section in respective manuscripts in the appendix. PCR amplification with 
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H2O instead of cDNA is used as a negative control. As endogenous controls to 
compensate for variable cDNA yields, GAPDH can be used for SYBR Green reactions, 
and 18S for TaqMan reactions. The platform used is ABI 7500 Fast real-time PCR 
system. 
 
 
 
3.2.10 Immunohistochemestry 
Immunohistochemestry (IHC) is used to determine the presence and cellular 
distribution of different proteins.  
Pluripotent SCs are fixed using paraformaldehyde (PFA). For surface markers, 
blocking of unspecific staining was performed by incubating the fixed cells with 10 % 
FBS diluted in PBS for 30 minutes followed by incubation with primary antibodies, 
diluted in 10 % blocking solution over night in 4 °C. 
For nuclear markers, blocking and permeabilization of the nucleus is performed by 
incubation in 2 % donkey serum, 0.1 % Triton-X and 0.1 % bovine serum albumin 
(BSA) in PBS for 2 hours at 4 °C. 
The secondary antibodies are diluted in 10 % blocking solution for surface markers or 
0.1 % Triton-X for nuclear markers and incubated for 2 hours at 4 °C in dark. 
 
DNA staining is performed by 10 minutes incubation with 1x Hoechst in PBS.  
 
3.2.11 FACS 
Pluripotent SCs should be harvest enzymatically to obtain single cells, and dilute them 
in 5 % FBS in PBS. Dilute primary antibody according to manufacturer’s 
recommendations and add cells. Incubate for 30 minute in 4 °C. After incubation wash 
cells with 5 % FBS in PBS. Add diluted secondary antibody and incubate for 30 
minutes in 4 °C and wash again to remove any unspecific binding of the antibodies. 
Figure 11. RT-qPCR. RNA is 
extracted from pluripotent SCs and 
cDNA synthesis is performed. 
Sequence of interest is detected either 
by using a primer pair, or by using a 
probe with an attached reporter dye. 
The amount of fluorescent released 
when the probe break-up is 
determined in Ct values, which are 
proportional with amplified product. 
   39 
Use a negative control antibody to set a threshold for scoring the proportion of cells that 
are positive for each test antigen. Typically this threshold should be set at the inflexion 
point on the negative control histogram, such that only 1-5 % of the cells stained with 
the negative control is scored “positive”. Using this threshold, the % cells scored 
positive with each antibody is recorded. 
A second region is set on the histogram, encompassing all cells – from this gate the 
“mean fluorescent intensity” of the cells stained with each antibody is recorded (Figure 
12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.12 Chromatin immunoprecipitation 
For ChIP analysis the commercially available kit LowCell#ChIP kit from Diagenode is 
being used, detailed protocol can be found in the kit. 
 
Cross-linking of the cells is performed using formaldehyde (FA). 
   
Chromatin shearing is performed by adding a buffer containing protease inhibitor to 
cross-linked cells. After incubating, the cells are sonicated for 10 minutes to obtain 
smaller fragments of DNA. Centrifuge sonicated samples and transfer supernatant to a 
new tube. A small amount of sample is used to determine the size of DNA fragments 
by running an agarose gel. 
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Figure 12 FACS. (A) The positive antibody stains cells substantial brighter than the negative 
control, nearly 100 % of the cells should be scored as antigen positive. (B) The positive 
histogram overlaps significantly with the negative control histogram, rather less than 100 % 
of the cells should be scored positive for this antigen. The mean fluorescence of cells stained 
with the test antibody in panel B will be substantially less than the mean fluorescence of the 
cells stained with the test antibody in panel A. The two numbers; mean fluorescence and % 
positive cells, provide two complementary numbers for comparing results between cells and 
antibodies.  
 40 
To bind antibodies to magnetic beads, a buffer mixed with protein-A magnetic beads is 
prepared. The specific antibodies are added to beads and incubate for 2 hours in 4 °C. 
 
Immunoprecipitate is performed by spinning tubes with antibody-coated beads and 
place in a magnetic rack before aspirating the supernatant. Add diluted sheareded 
chromatin in each tube in the rack. Save chromatin for input. Remove tubes and 
incubate on rotator over night in 4 °C. Wash and capture beads on magnetic rack. 
Aspirate the buffer and add DNA isolation buffer (also to input sample) and remove 
tubes from magnetic rack. Incubate all tubes in 55 °C for 15 minutes and then 100 °C 
for additional 15 minutes. Centrifuge and transfer supernatant to new tubes and analyze 
by qPCR (Figure 13). 
 
 
 
  
Figure 13 Chromatin Immuno-
precipitation. Crosslinking of harvested 
pluripotent stem cells is performed using 
formaldehyde. For smaller DNA fragments 
the fixated cells are sonicated. After 
sonication antibodies against modified 
histones are added and captured by protein-A 
beads. Reverse crosslinking is performed to 
remove antibodies and beads from 
modifications of interest. After DNA 
purification, PCR against the DNA sequence 
is performed. 
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4 RESULTS 
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he studies included in this thesis investigate effects on pluripotent Stem Cells 
due to handling and microenvironmental cues, such as cryopreservation and 
thawing, passaging methods, long term culturing and mutations caused by 
differentiation and culture. 
All four studies, two of them which have been published in peer-reviewed journals and 
one which is under revision, can be found in their entirety in the appendix.  
This section gives a brief overview of the results. 
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4.1 AN EFFECTIVE NON-SERUM XENO-FREE CHEMICALLY DEFINED 
FREEZING PROCEDURE FOR HESCS AND IPSCS 
Traditionally, DMSO ((CH3)2SO) is the most commonly used cryoprotectant for long-
term storage of pluripotent stem cells. It is an organosulfur compound which have 
relatively high freezing point (18,5 °C) meaning that it, at lower temperatures is solid 
which can limit its utility in chemical processes, in this case, crystallization with 
cooling. It can permeate the cell membrane without damaging the cell. It is mostly used 
in a 10% dilution with cell culture media. However, DMSO can be toxic to stem cells 
and may be one of the reasons for the low survival rates post freezing.  
 
STEM-CELLBANKER also contain DMSO, but a second non-permeable 
cryoprotectant in the solution helps even out the ice-formation outside of the cells, 
while DMSO penetrate the membrane, crystallizing the water inside the cells. This 
way, the cells are less likely to burst due to the ice-formation.   
 
We have used two hESC lines (HS293 and HS306 both derived at Karolinska 
Institutet) and one hiPSC line. The hiPSC lines CHiPS A have been established in 
collaboration with University of Geneva92 by transducing human skin fibroblasts with 
OCT4, NANOG, SOX2 and LIN28.  The experimental design was to characterize these 
three cell lines before cryo-storage, and after thawing, to look for any indication of 
affected properties of the cells. Both hESCs and iPSCs are highly sensitive to cryo-
injury caused by cryopreservation which has limited their utility80, 83-88. 
All cell lines were cultured in the same manner prior to cryopreservation. The 
undifferentiated colonies were mechanically harvested and frozen either with the 
conventional method using 10 % DMSO in culture medium (20% knockout SR, 2 mM 
glutamax, 0,5 % penicillin-streptomycin, 1 % non-essential amino acids, 0,5 mM 2-
mercaptoethanol and 8 ng/ml basic FGF) or using the ready-to-use freezing solution 
STEM-CELLBANKER.  
 
We found that there were differences between the two different methods, 10 % DMSO 
and the method using STEM CELLBANKER. 
 
By counting cells using the trypan blue exclusion method in a haemocytometer, we 
found significant differences between the two methods in the number of surviving cells 
after freeze-thawing. hESC line HS293 had 93 % survival after thawing and HS306 
displayed 96 % survival when using the new method, compared to 49 % survival of 
both cell lines frozen with the standard method. The hiPSC line CHiPS A also 
displayed better survival after thawing with the new method, 90 % survival compared 
to 50 % in standard method. The number of colonies that survived freezing was fewer 
in the standard method compared to the new method using STEM-CELLBANKER, 
this was also verified using calcein-esterase based live-dead assay. 
In order to control the recovery of the cells, growth curves during the first passages 
after thawing were performed. 
 
The freeze-thawed cells from both methods were also stained positive for antibodies 
against the pluripotency markers OCT4, NANOG, TRA1-81 and SSEA4.  The level of 
pluripotency in frozen-thawed cells was also controlled by Real time-quantitative PCR 
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(RT-qPCR) for OCT4 and NANOG. We did not find any significant differences in the 
pluripotency markers expression between the two methods  
Lastly, the cells were karyotyped to ensure that they had not acquired any chromosomal 
changes due to the cryopreservation. The teratoma formation showed that the cells did 
form tissues represented in the three germ layers (Endoderm, Mesoderm and 
Ectoderm). 
 
The advantages using STEM-CELLBANKER instead of 10 % DMSO: 
 
Significantly increased cell viability while maintaining cell pluripotency 
(HS293 P=0.0019 and HS360 P=0.0030), normal karyotype and proliferation 
ability after freeze-thaw procedure. 
 
Safer cryopreservation with medical graded ingredients, no risk of 
contamination of animal-derived components. 
 
Save time/cost/steps with the complete formulation, no further preparation, 
direct freezing at -80 °C without having to use a programmed freezer.  
  
   45 
4.2 PASSAGING TECHNIQUES AND ROCK INHIBITOR EXERT 
REVERSIBLE EFFECTS ON MORPHOLOGY AND PLURIPOTENCY 
MARKER EXPRESSION OF HESCS 
Previous reports have shown that the use of the ROCKi decreases the cellular stress 
response and apoptotic cell death in pluripotent stem cells when dissociated from each 
other during passaging101 and even cryopreservation83. These observations resulted in a 
wide usage of this inhibitor among scientists.  
 
By studying the morphology of hESCs we found differences between cells that had 
been passaged mechanically, to those passaged enzymatically with addition of ROCKi 
to escape the dissociation-induced apoptosis. Mechanically passaged cells kept growing 
in typical SC colonies, with a time frame of approximately 5-6 days between each 
passage. Enzymatically passaged cells pre-treated with ROCKi produced more colonies 
in a shorter time frame than those passaged mechanically. Cells which were not treated 
with the inhibitor, but passaged enzymatically grew slower and produced fewer 
colonies. This could be an indication of selection of cells with a growth advantage 
when adding the inhibitor, where enzymatically passaged cells without ROCKi are the 
truly pluripotent ones. 
 
ROCK was initially discovered as a downstream target of the small GTP-binding 
protein Rho which is involved in the regulation of many cellular processes such as 
growth, adhesion, migration and apoptosis by controlling actin cytoskeletal assembly 
and therefore cell contraction130. By staining cells passaged using these three passaging 
methods it was discovered that both mechanically and enzymatically passaged cells had 
organized and dynamic organized actin filaments indicating that the cells were under 
stress. Cells passaged with ROCKi did show a much more disorganized structure of the 
actin filaments, in order with previous suggestion that the addition of ROCKi during 
passaging reducing the amount of stress in cells caused by passaging.  
However, cells from all three passaging techniques expressed positive 
immunoreactivity for the pluripotency marker. The staining also demonstrates an 
enlargement of the nucleus in enzymatically passaged cells, which was confirmed by 
measuring nuclear area.  
 
The main purpose of passaging pluripotent SCs, besides expanding cells, is to maintain 
their pluripotent state and therefore avoid spontaneous differentiation. When analyzing 
the cells with RT-qPCR we found a dramatic decrease in gene expression of the most 
common pluripotency markers; OCT4/POU5F1, NANOG, SOX2, KLF4 and IGF2, 
using passaging methods where cells had been dissociated from each other, and treated 
with ROCK inhibitor. C-MYC which is a marker associated with cancer cell 
characteristics were not expressed in any of the analyzed cell lines. Also no expression 
levels of H19 were detectable. H19 is a gene for long non-coding RNA, exclusively 
expressed on one parental allele in imprinting, which seems to play a role in some 
cancers.  
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The differences in the gene expression profile of different passaging methods correlated 
poorly with an analysis of histone modifications in the promoters of the same genes as 
assessed by chromatin immunoprecipitation (ChIP). 
Due to the increased area of the nucleus found in the staining we speculated whether 
there could be a general effect on the chromatin structure that obscured more specific 
differences in histone lysine methylation between the different passaging techniques. 
Due to this we included a modification influencing the histone-histone interaction, 
higher order chromatin structure and nucleosome organization; H4K16ac. However, 
there were no significant differences detected between the different passaging 
techniques.  
We also included another epigenetic mark associated with transcription start site of 
active genes; H3K4me3, and to marks associated with repressed genes; H3K9me3 and 
H3K27me3. We could not find any correlation between the decrease in gene expression 
and histone modification, suggesting that the effects are only located in the mRNA. 
To evaluate whether these effects on the morphology and gene expression were 
permanent, cells passaged enzymatically with and without ROCKi were now passaged 
mechanically instead. After the transition between the different passaging methods the 
cells were cultured for several passages in the standard method (mechanically) and then 
re-analyzed. We found that the earlier decreased levels in gene expression of the most 
commonly used pluripotency markers were back to normal levels. Cells passaged with 
ROCKi had a mean expression between the three hESC lines used of 93 % of 
OCT4/POU5F1 and 104,1 % of NANOG. Cells enzymatically passaged without 
ROCKi had a mean expression between the three different hESC lines of 125,6 % for 
OCT4/POU5F1 and 108,4 % for NANOG. All compared with 100 % expression of the 
markers for cells passaged mechanical throughout the study. This indicates that the 
effects were reversible and a direct response to the different passaging techniques. 
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4.3 HISTONE H4 LYSINE ACETYLATION AND RELATIVE GENE 
EXPRESSION OF PLURIPOTENCY MARKERS IN HESC AND HIPSC 
LINES 
Earlier studies show that the ATP-dependant chromatin remodeling complex SWI/SNF 
is associated with histone modification, especially histone acetylation of lysine 8 and 12 
on histone H4131. Due to this, we wanted to investigate if we could correlate gene 
expression of OCT4, SOX2, NANOG and KLF4, with histone acetylation on the 
promoters of the same factors. We focused the histone acetylation analysis of H3K8 
and H4K12 since acetylation of these two specific residues have been associated with 
the SWI/SNF complex as well as DNA repair of DSBs. 
 
To see whether high passage numbers correlate with gene expression and histone 
acetylation, our study aimed at investigating differences in gene expression levels and 
the levels of histone acetylation between low and high passage numbers. Different cell 
lines have distinct differentiation potential, which may be affected by high passaging 
numbers of pluripotent SC, exhibiting increased DSBs and DNA repair. 
 
In this study we compared two hiPSC lines; CHiPS A and CHiPS W, and three hESC 
lines; HS346, HS361 and HS401. As a negative control line we included the fibroblast 
line (hff), from which the hiPSC lines were reprogrammed. 
 
RT-qPCR was performed to detect mRNA levels of depicted pluripotency factors 
associated with stemness; OCT4, NANO, SOX2 and KLF4. RT-qPCR was performed 
on three hESC lines and two hiPSC lines of different passaging numbers, with the 
parental fibroblast line as a negative control. 
We could identify differences in relative expression levels between the different 
pluripotency markers. However no clear difference between the different passages was 
found, suggesting that cells which have been in culture for a long period of time do not 
differ significantly between low-passage counterparts. We could also not find any 
differences in gene expression levels between hESC lines compared with hiPSC lines.  
However, there were differences in levels of pluripotency marker expression between 
the hiPSC lines CHiPS A and CHiPS W. CHiPS W show constant lower levels relative 
gene expression of all four studied pluripotency markers.  
 
When analyzing the relative acetylation levels of lysine 8 and lysine 12 on histone H4 
on the promoters of the pluripotency markers using ChIP, we expected to find that cell 
lines with a higher passage number would have more signs of DSBs, and therefore have 
increased levels of acetylation. We could not detect any such correlation between 
passage number and the relative acetylation levels of DSB-associated residues H4K8 
and H4K12 on the promoters of the studied pluripotency markers. 
We could on the SOX2 promoter of both hiPSC lines CHiPS A and CHiPS W detect 
lower levels of relative acetylation of both residues, H4K8 and H4K12, compared to 
the hESC lines, which all have similar levels of acetylation. In the promoter region of 
KLF4 a small, but not statistically significant, differences between the two hiPSC lines 
was found. CHiPS W had a higher level of relative acetylation on both residues, 
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compared to CHiPS A, however the levels of both residues are similar in the individual 
hiPSC lines.  
 
The studied lysine residues 8 and 12 on histone H4 has been associated with DSBs and 
also to BRG1, which is one of the SWI/SNF components. Due to the lack of correlation 
between passage numbers and the relative acetylation levels, we hypothesized whether 
there would be a correlation in relative acetylation levels and gene expression between 
the two different lysines on histone H4 on the promoters of the pluripotency markers 
OCT4, SOX2, NANOG and KLF4. No significant correlation was however detected. 
The gene expression levels and promoter acetylation of lysine 8 and lysine 12 of the 
most studied markers have poor correlation to each other, but also to pluripotency 
potential. Epigenetic modifications other than H4K8 and H4K12 are most likely 
involved in the regulation of characteristics of hESCs and hiPSCs.  
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4.4 IN VIVO DIFFERENTIATED HESCS CAN ACQUIRE CHROMOSOMAL 
ABERRATIONS MORE FREQUENTLY THAN IN VITRO DURING THE 
SAME PERIOD 
 
Three hESC lines, HS346, HS366 and HS368 were used to study chromosomal 
stability during long term culture. hESCs can be affected of microenvironmental 
conditions which may lead to chromosomal alterations. In vitro and in vivo conditions 
were studied using high-resolution Affymetrix SNP 6.0 array DNA copy number 
variations (CNVs) and fluorescent in situ hybridization (FISH) analyses.  
 
All three hESC lines cultured and maintained on a feeder layer of human foreskin 
fibroblasts were analyzed at passage 27 (HS346), 42 (HS366) and 28 (HS368). The 
cells were karyotypically normal, expressed immunocytochemical surface markers 
(SSEA-4, TRA-160 and TRA-180) and nuclear markers (NANOG and OCT4). The 
mRNA expression levels confirmed that the cells were in a pluripotent state using 
quantitative RT-PCR. The cells also formed solid teratomas with components of 3 
primitive embryonic germ layers when implanted beneath the testicular capsule and 
subcutaneously of a young SCID mouse. 
 
SNP arrays for HS364 at starting passage 27 revealed 9 variations on different 
chromosomes, after 7 additional passages this cell line did not gain any additional 
mutations. However, after being differentiated in vivo this cell line showed an 
amplification of a whole X chromosome, and had a higher degree of mutations with 67 
variations (compared to the 9 variation from in vitro cultures), most variations were 
gains and mostly clustered on chromosome X, suggesting an extra X chromosomal 
material.  
The FISH analysis of the same in vivo differentiated cells showed normal pattern of 
XY in 58 % of the cells (one X centromere and 2 SHOX signals), whereas 24 % 
showed two X centromere signals and 2 SHOX signals. A pattern consistent with 
duplication of the X chromosome, suggests mosaicism for XY and XX (with lost Y 
chromosome) cells. This confirms the result of extra X chromosome material from the 
SNP array.  
 
SNP arrays for cell line HS366 at passage 42 show a total of 6 alterations, after 
growing for 7 more passages, a loss registered on chromosome 17p11.2 had 
disappeared from the cells. 
 
Cell line HS368 had 10 variants at passage 28. After 8 weeks in the teratoma (testis) a 
new gain appeared on chromosome X encompassing about 150 kb of the 
pseudoautosomal gene-rich region PAR1 (ZBED1, which may have a role in cell 
proliferation) and CD99 which may act as a oncosuppressor. In another teratoma we 
found 8 more mutations gained after 8 weeks of in vivo differentiation. 
Interphase FISH analysis showed that 74% of the cells had normal XY content, 
whereas 21% showed X centromere signal and 3 SHOX signals.  This implicated a gain 
of the pseudoautosomal regions, consistent with the results of the SNP array.  
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In summary, a total of 12 solid teratomas were generated from the 3 hESC lines used in 
this study. DNA was extracted from the teratomas after harvest and analyzed by the 
high-resolution Affymetrix SNP 6.0 array. Cells at the same passage as the injected 
ones were cultured in vitro up to 8 weeks, until teraromas were extracted, to compare 
their developmental adaptation capacity with the in vivo developing cells.  We assessed 
the genomic variations by in vitro and in vivo growth. We observed increased mutation 
coverage of about 30% (median).  
 
 
 
Line Tissue Passage Mutation 
coverage (kb) 
Change in mutation coverage in 
respect to in vitro growth 
HS364 Cells in 
vitro 
34 3,609  
HS364 Teratoma  4,702  
    30% (median) 
HS366 Cells in 
vitro 
49 714  
HS366 Teratoma  1,581  
    121% (median) 
HS368 Cells in 
vitro 
35 3,298  
HS368 Teratoma  4,239  
    29% (median) 
   Total 30% (median) 
 
 
The results from this study where we found that structural variants exist in 3 hESC 
lines which are otherwise karyotypically normal have also been addressed in a study 
published by the International Stem Cell Initiative (ISCI)56. By analyzing 125 hESC 
lines and 11 hiPSC lines from 38 laboratories in 19 different countries we searched for 
common genetic changes that could occur during prolonged culture, some cells of 
which maintained in a pluripotent state for many passages might be subject to strong 
selection, and variants that would enhance the probability of self renewal would be 
favored.  
  
Table 2. Mutation coverage (in kb) in teratomas compared to in vitro cell growth (from paper IV) 
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5 DISCUSSION 
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enetic stability and stable stem cell characteristics of pluripotent SCs is 
important for both clinical applications and scientific research. Abnormalities 
occurring in sensitive areas of the genome are likely to result in marked 
changes in functional and biological effects. This leads to loss of application value, 
aiming towards using cells with as little effect on their characteristics as possible.  
The benefit to culture pluripotent SCs without influencing their characteristics requires 
well-established and risk-evaluated techniques. In the future this knowledge will be 
invaluable to this field where the hope is to direct the production of tissue specific cells 
to replace part or whole damaged or diseased organs.  
 
 
 
 
  
G 
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From the perspective of future therapeutic applications, the banking of pluripotent SCs 
requires optimized cryopreservation systems which are defined, xeno-free, economic 
and can be performed under good manufacturing practice (GMP).  
So far low efficiency and laborious techniques have limited the procedure where 
pluripotent SCs can be stored for long periods of time in liquid or saturated nitrogen.  
It is important with an effective system to store large amount of cells for research, but 
most importantly for clinical use, where large amount of cells may be necessary to use 
for patients with an urgent need of cell therapy, where culture of new cells for each 
patient may have a limited time-frame. For that reason a freezing and thawing medium 
to cryopreserve and facilitate long-term storage of large quantities of pluripotent SCs is 
important without losing cells when thawing is crucial.  
 
We have shown in Study I that a combination of both permeating and non-permeating 
cryoprotectants has limited the direct cell injury induced during freezing by reducing 
both the extracellular ice formation (EIF) and intracellular ice formation (IIF). This 
unique combination of a non-permeating cryoprotectant that keeps the water molecules 
from producing ice crystals causing the cells to dehydrate and shrink, and a permeating 
cryoprotectant that keeps the water molecules within the cells to freeze and therefore 
keeping the cells from bursting due to the expansion that crystal formation causes.  
Unlike cells frozen slowly, vitrified colonies have consistently shown very high 
survival and re-attachment rate80, 85, 132. Vitrification transforms the intracellular 
medium into a glasslike structure which prevents the formation of IIF. However, the 
cooling rates needed for successful vitrification require that the sample volume is kept 
low, resulting in that only few hESC or hiPSC colonies can be cryopreserved in one 
straw which is originally designed for small quantities such as oocytes and embryos. In 
2008 a bulk vitrification system was described for the first time133. In addition to the 
technical difficulties, another major problem with these vitrification methods is that 
they are open systems. For clinical grade cryostorage, sterile liquid nitrogen would be 
needed, requiring a specific vacuum filtration system for the liquid nitrogen. The open-
pulled straws that are being used can of course be stored in closed vials in the gas phase 
of liquid nitrogen but this does not prevent the original contact during the vitrification 
procedure. Also, handling of different vitrification solutions in various concentrations, 
together with several incubation steps, is more likely to have technical drawbacks with 
the bulk vitrification method, rather than the new easy and safe method presented in 
Study I, which has fewer crucial steps. Previously, freezing stem cells with only 
permeating cryoprotectants has been used, but the two cryoprotectants combined in this 
novel cryopreservation system have been shown to not only give good survival in 
pluripotent cells, but we have also found that this system give better results in somatic 
cells, such as human hepatocytes (P<0.01) compared to DMSO in the University-of-
Wisconsin solutions (DMSO-UW)134. 
 
To further enable the use of pluripotent SCs in the future; it is important to keep the 
cells from undergoing spontaneous differentiation. In Study II we have shown that cells 
being passaged mechanically using a surgical scalpel or cell scraper have minimum 
impact on the expression levels of the pluripotency markers OCT4, NANOG, KLF4 
and SOX2. The organized stress fiber formation found in these cells may however 
indicate that the cells are under stress, which might be due to mechanical-induced 
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damage that the cells are subject to when cutting in a cell colony by hand using a 
scalpel.  
On the other hand, cells that undergo an enzymatic treatment in order to be passaged, 
display a different morphology, decreased level of expression of pluripotency markers 
and an enlargement of the nucleus, quantified by area size. As the mechanical passaged 
cells, they exhibit organized stress fiber formation which indicate stress.  
Enzymatical passaged cells with ROCKi also had a different morphology and 
decreased expression levels of pluripotency markers. However, unlike cells without 
ROCKi, the cells did not display organized actin filaments. This indicates that even 
though levels of pluripotency markers are decreased, the cells show no sign of stress as 
a result of passaging, in line with earlier data about ROCKi decreasing cellular stress101. 
The precise regulation of the structure and dynamics of the actin cytoskeleton is 
essential for many vital developmental and physiological processes, and abnormalities 
in actin dynamics are associated with many pathological disorders135. The large amount 
of impact on cells due to passaging techniques could be an indication that, in our hands, 
dissociation of cells into single cell suspension has a clear negative effect on the cells 
pluripotency, but ROCKi keep the cells in a state with less stress.  
Earlier published work has suggested that the addition of ROCKi would overcome 
problems such as apoptosis, with no impact on hESC characteristics101. However our 
cells seem to react differently with ROCKi. Even though ROCKi reduces levels of 
stress when being dissociated, their characteristics are affected in regard of their 
pluripotent state with a drop in pluripotency marker expression. In this study we can 
also see a difference between the enzymatically passaged cells with ROCKi added, and 
the cells that were enzymatically passaged without the inhibitor. Cells passaged without 
the inhibitor did seem to undergo programmed cell death to a larger extent than the 
cells with the inhibitor, known as an apoptosis inhibitor. Also, cells passaged without 
ROCKi exhibit lower proliferation rates, leading to less colony formation. Together 
with organized stress fiber formation, comparable with those found in mechanical 
passaged cells, this suggest that ROCKi may have led to the survival of cells which 
without the addition of the inhibitor would have been excluded by apoptosis, due to 
their lost stem cell characteristics.  
The loss in expression of pluripotency marker could potentially be an indicator that the 
cells were heading towards cancerogenic properties, but the oncogene c-MYC were not 
detected in these cells, neither at gene expression level nor on the promoters of these 
genes. 
The fact that these cells with the decrease in expression of pluripotency markers did not 
have any correlation with the acetylation or methylation of epigenetic marks for active 
or repressed genes, may be one of the explanations why these effects were reversible, 
where the effect only seemed to be measurable on a mRNA level and not in the 
chromatin state of the promoters. The reversible passaging may therefore have led to 
the selection and survival of the truly pluripotent cells for each further passage. These 
finding demonstrate the importance of caution when cells are being passaged using 
different techniques. 
During the revision of this manuscript we are performing FACS and western blot in 
order to determine if we can detect differences also on the protein level. 
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Not only passaging techniques influence the pluripotent SCs. The occurrence of genetic 
and epigenetic changes in hESC lines and hiPSC lines in early or late passages are also 
important in respect to their use in regenerative medicine. In study III we hypothesized 
that cells kept in culture for many passages exhibit larger amount of DSBs, than found 
in cells from early cultures.  
Downs and co-workers showed by ChIP analysis that DSB in mammalian cells induce 
acetylation of several lysines, namely 5, 8, 12 and 16 within histone H4108.  
The chromatin remodeling complex SWI/SNF was found at DSB sites in budding 
yeast136-137 and was therefore believed to have an important role in DSB repair by 
altering nuclesome positions at the site of DSBs. The complex contains a core ATPase, 
either BRG1 or BRM, plus seven or more non-catalytic subunits138. SWI/SNF-type 
chromatin remodeling complex is present in all eukaryotic cells, where they act in an 
ATP-dependant manner to disrupt chromatin structure and facilitate the binding of 
transcriptional regulators at nucleosomal sites. The activity of SWI/SNF complex is 
crucial for proper differentiation and development139. 
It was found when studying a major repair pathway for DSBs called non-homologous 
end joining (NHEJ) where two broken DNA ends are joined together. Acetylation of 
histones located at DSBs by the HATs CBP/p300, results in the recruitment of BRG1 to 
facilitate for the chromatin remodeling complex SWI/SNF to alter the nucleosomes131. 
Particular lysine 18 on histone H3, but also on lysines 8 and 12 (among others) on 
histone H4 are acetylated during DSBs140.  
Our study investigating epigenetic changes in cells from early and late passages both in 
hESC lines and hiPSC lines, looking at lysines 8 and lysine 12 on histone H4 did not 
indicate that these specific marks were involved in the acetylation of histones on sites 
of DSBs. We have been looking at the promoter region of genes associated with 
pluripotency, but also the oncogene c-MYC. c-MYC is one of the four factors used to 
reprogram the hiPSC lines used, and it has been shown that the regulation of c-MYC 
expression is profoundly dependent on the activity of the SWI/SNF complex. It is 
therefore believed to play an important role in reprogramming where SWI/SNF 
promotes reprogramming by interacting with c-MYC. First SWI/SNF activates the 
expression of c-MYC and thereafter recruits SWI/SNF to the promoter of the 
pluripotency factors to enhance their reprogramming. At the same time, the SWI/SNF 
complex is recruited on the promoters of differentiation genes and maintain these genes 
in a repressed state, and finally the somatic cells are induced into iPSCs141. To 
investigate whether DSBs are more common in cells in late passage compared to early, 
there are other possible genes to investigate, such as BRG1. BRG1 is, as mentioned, 
one of the subunits of the SWI/SNF complex having enzymatic activity and also as a 
bromodomain, that recognizes acetylated lysine residues such as those on N-terminal 
tails of histones.  
Staining for γ-H2AX, a gene coding for H2A, which becomes phosphorylated on serine 
139 as a reaction of DSBs, could therefore be measured to evaluate its activity in 
damage response. 
Due to the lack of correlation between gene expression and acetylation of the two 
studied lysines, it is possible that other epigenetic modification play a more important 
role in the regulation of stem cell characteristics of pluripotent SCs, for example 
acetylation on histone H3. It has been suggested that SWI/SNF stimulates H3 
acetylation by facilitating S139ph and by studying knock-down BRG1 it was found that 
acetylation at K9, K14, K18 and K23, but not at K27, were largely decreased by 
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SWI/SNF knockdown, but methylations at most residues were not affected by 
SWI/SNF knowdown142. 
Other studies have linked the enzyme DNA topoisomerase IIβ-dependent DSBs and the 
components of the DNA damage and repair machinery in regulated gene 
transcription143, it could therefore be of interest to study this enzyme in correlation with 
promoter regions of the genes associated with pluripotency. 
It is possible that methylation of the DNA and not methylation of histone tails could be 
more important when looking at epigenetic changes in late passage, comparing hESC 
lines and hiPSC lines. Recent studies have identified differences in DNA methylation 
between hESCs and hiPSCs144-145. By studying iPSCs generated from somatic cells 
from all three germ layers and comparing them with their original un-reprogrammed 
cells it was found that early passage iPSCs retain a transcriptional memory of the 
original cell, which could be explained by incomplete promoter DNA metylation146.  It 
is possible that the hiPSC lines used in Study III in early passage exhibit more DSBs 
originating as a transcriptional memory from the fibroblasts that they originally 
reprogrammed from, which might be lost in later passages. By studying DNA 
methylation this could possibly identify differences between hiPSCs and hESCs, and 
early and late passage which could be correlated with differences in gene expression.   
 
hESC lines destined for therapeutic use should have a normal genetic composition, 
however, keeping cells in culture for prolonged periods may result in genetic instability 
of the cells, and the possibility that these cells may possess the ability to produce 
tumors in vivo present a major challenge.  
Our findings in study IV where larger chromosomal changes in teratomas in vivo was 
discovered compared with the same cells cultured in vitro in parallel with the teratoma 
growth may influence the potential use of these cells. The three different hESC lines 
used in this study revealed that the mutation rate differ between different cell lines, 
suggesting that there are variations to what extent the cells are prone to undergo 
mutations. As pointed out, the increased mutation rate of up to 30% in the teratomas 
suggest that while adaptation to the in vitro environment is already achieved, and the 
rates of new mutations are small, when injected into mice, the stem cells have to re-
adapt to their new environmental conditions, which may cause the increased mutation 
coverage. The period of 8 weeks that the teratomas grew in the mice is a relatively 
short period, and it remains unclear whether the mutation coverage would increase with 
time and also be of more malignant types, or if the mutations are acquired within the 
first cell divisions and thereafter remain stable. To assess safe clinical use of these cells 
more studies are necessary. The tissues seen after an 8-week period did not contain any 
malignant features and were not invasive or metastatic, however it is not possible to 
study whether this would change after a longer period, since it is, of ethical reasons, not 
possible to keep the teratomas in the mice for longer periods. This result shows the 
importance of awareness when transplanting these cells, and the risks of not fully 
removing pluripotent cells from the cell populations aimed to be transplanted. As 
known to date, differentiated cells no longer have a teratoma-forming capacity, but our 
results underline the importance of more detailed genetic testing of pluripotent SCs 
before their clinical application in regenerative medicine, and not only cytogenetic 
testing.  
It is known that a large portion of early human embryos are chromosomally abnormal, 
often due to the fact that embryos with poor morphological or developmental delays are 
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the ones donated to research and are used to derive new lines, whereas the normal ones 
are used for the patients undergoing fertility treatment in first hand. The large mutation 
coverage in one of the three lines in this study could potentially be due to this, since it 
has been shown that there is no correlation between embryo morphology and success in 
deriving new hESC lines126. However it is most likely that the vast majority of the 
mutations found are due to culture adaptation and microenvironmental conditions when 
being xeno-grafted, and that for clinical applications it will be important to minimize 
the time in culture.  
 
Another mechanism that could potentially contribute to the genomic instability of 
hESC lines could be the abnormal DNA repair system found in pluripotent SCs but not 
in somatic cells whereby the mitotic spindle assembly checkpoint is functional but does 
not initiate apoptosis as it does in somatic cells147. 
These observations of the extent of CNVs in the genome in hESCs leaves an open 
question regarding the extent to which CNVs account for hESC genomic variability 
and whether individual hESC lines have characteristic gains or losses of genetic 
material that may influence their replication, proliferation, differentiation or functional 
potential. It is known that extra copies of chromosome X may lead to an increased 
dosage of a gene or genes that favor self-renewal. Most of the 67 variations found in 
the teratoma cells from HS364 were clustered on the X chromosome, suggesting that 
the cells have extra X chromosomal material. Recently, it has also been shown that iPS 
cells can acquire mutation during their derivations, although many of these mutations 
are lost on subsequent passaging148. 
 
  
Figure 14. Thesis summary. There are many aspects to consider before pluripotent SCs can be 
used for patients in a safe manner. (A) We have shown that passaging techniques influence the 
stem cell characteristics when using different techniques, and (B, C) there are variations in gene 
expression and acetylation profiles in different cell lines, but no detected correlation between them 
(D). Pluripotent SCs gain more genetic mutations in vivo, than in cells cultured in parallel in vitro. 
The mutations gain were especially located on chromosome X, known to be involved in growth 
advantages. (E) To keep pluripotent SCs cryopreserved and ready for patients we identified a 
freezing system with minimal effect on SC characteristics.    
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6 CONCLUSION 
Over the past few decades, the scientific community has continued to build a 
remarkable understanding of the complex nature of SCs. Through the four studies in 
this thesis we have clarified a few of the obstacles of using pluripotent SCs.  
 
The cryopreservation system using CELLBANKER together with the 
thawing solutions results in better survival of pluripotent SCs compared 
to the more laborious techniques using only one cryoprotectant.  
 
Different passaging methods do affect the gene expression of the most 
commonly used pluripotency markers, however the effects seen are not 
permanent and can therefore be reversed by using a non-enzymatical 
technique.   
 
Acetylation of lysine 8 and lysine 12 on histone 4 which have previously 
been described to be important in the recruitment of the SWI/SNF 
complex at DSB sites does not seem to be the main acetylated lysines 
involved in regulation of pluripotency in both hESC and hiPSC lines.  
 
Larger chromosomal changes were found by SNP analysis in in vivo 
cultured cells within teratomas, than in in vitro cultured pluripotent SCs. 
This was probably due to mosaicism for XY and XX cells present in 
teratomas, which was revealed by FISH analysis. 
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